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Abstract 
The P-glycoprotein is an efflux pump belonging to the superfamily of ABC transporters, and 
promotes the outward transport of a wide range of structurally unrelated compounds, thus 
playing important physiological functions. Though its primary function is the protection of 
cells against toxic xenobiotics and endogenous metabolites, this membrane transporter also 
plays a relevant role in drug pharmacokinetic processes. 
Recently, our group showed that newly synthesized thioxanthonic derivatives protected 
against toxic P-gp substrates, acting as potent inducers/activators of this transporter. 
Therefore, it is essential to discover new P-gp modulators and enlightening the 
stereoselectivity of this ABC transporter face to this class of modulators. In this dissertation, 
eight chiral thioxanthonic derivatives (ATx's 1-8) were synthesized by Ullmann cross 
coupling reaction between the thioxanthone derivative 1-chloro-4-propoxy-9H-
thioxanthen-9-one (Tx) and eight enantiomerically pure building blocks (A 9-16). The 
structure elucidation of all synthesized compounds was carried out by spectroscopic 
methods, including IR, NMR (1H, 13C, HMBC and HSQC), and their purity evaluated by 
HPLC.  
The evaluation of P-gp modulation of all the synthesized chiral thioxanthonic derivatives 
was, then, performed in vitro, in order to study the influence of the stereochemistry on P-
gp induction and activation. Several biological activity assays were performed using Caco-2 
cells as an in vitro model of the human intestinal epithelium.  
The data from P-gp expression showed that ATx 2 and ATx 6 were the only thioxanthones 
which significantly increased P-gp expression, when compared to control cells. However, all 
the tested compounds significantly decreased the RHO 123 intracellular accumulation, that 
was evaluated in the presence of the tested ATx’s, thus reflecting a significantly increased 
P-gp activity. Since this assay allows the evaluation of potential immediate effects of the 
compounds on P-gp activity, as a result of a direct activation of the pump, it was possible to 
conclude that ATx's 1-8 were P-gp activators. The RHO 123 accumulation assay in Caco-2 
cells pre-exposed to the tested ATx’s for 24 hours, demonstrated a significant decrease in 
RHO 123 intracellular accumulation for all compounds, with exception of ATx 3, thus also 
reflecting an increased P-gp activity. Since ATx 1, ATx 4, ATx 5, ATx 7 and ATx 8 were not 
able to significantly increase P-gp expression, the increase in its activity may result from a 
direct pump activation.  
No significant differences in the levels of P-gp expression and activity were observed 
between the isomers (R) and (S) of each enantiomeric pair, suggesting that P-gp modulation 
may not be significantly affected by enantioselectivity concerning this class of compounds
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Resumo 
A glicoproteína-P (P-gp) promove o transporte para o exterior das células de uma vasta 
gama de compostos estruturalmente não relacionados, desempenhando assim importantes 
funções fisiológicas. Embora a sua principal função seja proteger as células contra 
xenobióticos tóxicos e metabolitos endógenos, este transportador de membrana 
desempenha também um papel relevante nos processos farmacocinéticos. 
O nosso grupo demonstrou recentemente que novos derivados tioxantónicos obtidos por 
síntese protegem contra substratos tóxicos da P-gp agindo como indutores/ativadores 
potentes deste transportador. 
Portanto, é essencial descobrir novos moduladores da P-gp e esclarecer a 
estereoselectividade deste transportador ABC relativamente a esta classe de moduladores. 
Neste trabalho, oito derivados tioxantónicos quirais (ATx’s 1-8) foram sintetizados por 
reação de acoplamento de Ullmann entre a 1-cloro-4-propoxi-9H-tioxanten-9-ona (Tx) e 
oito blocos construtores enantiomericamente puros (A 9-16). A elucidação estrutural de 
todos os compostos sintetizados foi realizada por métodos espectroscópicos, incluindo IV, 
RMN (1H, 13C, HMBC e HSQC), e a sua pureza foi avaliada por HPLC. 
A avaliação da modulação da P-gp por parte dos compostos sintetizados foi, em seguida, 
realizada in vitro, a fim de estudar a influência da estereoquímica na indução e ativação da 
P-gp. Vários ensaios de atividade biológica foram realizados utilizando células Caco-2 como 
modelo in vitro do epitélio intestinal humano. Os resultados de expressão da P-gp 
mostraram que ATx 2 e ATx 6 foram as únicas tioxantonas testadas que aumentaram 
significativamente a expressão da P-gp, quando comparados com os resultados obtidos com 
as células controlo. No entanto, todos os compostos diminuíram os níveis intracelulares de 
RHO 123, que foram avaliados na presença das ATx's testadas, refletindo assim um 
aumento significativo na atividade da P-gp. Uma vez que este ensaio permite avaliar o 
potencial efeito imediato dos compostos testados na atividade da P-gp, como resultado de 
uma ativação direta da bomba, foi possível concluir que as ATx's 1-8 são ativadoras da P-
gp. O ensaio de acumulação de RHO 123 em células Caco-2 pré-expostas às tioxantonas 
testadas durante 24 horas, demonstrou uma diminuição significativa na acumulação 
intracelular de RHO 123 para todos os compostos, com a exceção da ATx 3, refletindo 
igualmente um aumento significativo da atividade da P-gp. Visto que ATx 1, ATx 4, ATx 5, 
ATx 7 e ATx 8 não foram capazes de aumentar significativamente a expressão da P-gp, o 
aumento na sua atividade pode resultar de uma ativação direta da bomba. 
Não foram observadas diferenças significativas nos níveis de expressão e atividade da P-gp 
para os isómeros (R) e (S) de cada par enantiomérico; portanto a modulação da P-gp parece
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 não ser significativamente afetada pela enantioselectividade no que respeita a esta classe 
de compostos. 
Palavras-chave: atividade biológica, enantiosselectividade, farmacocinética, 
glicoproteína-P, modulação da P-gp, tioxantonas. 
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General and Specific Objectives 
 
The main objective of this dissertation was the synthesis of new small chiral 
molecules and their evaluation as potential modulators of P-glycoprotein. 
  
The specific objectives of this dissertation were: 
 To synthesize a library of thioxanthones in an enantiomerically pure form by 
coupling reactions of a suitable functionalize thioxanthone with chiral 
building blocks; 
 The structure elucidation of the chiral thioxanthones; 
 To evaluate the purity of the synthesized chiral thioxanthones by high 
performance liquid chromatography; 
 Screening the potential modulatory effect on P-gp expression and activity, in 
order to evaluate the in vitro behaviour for both enantiomers. A P-gp ATPase 
assay was performed for characterize the compounds that interact with P-gp, 
namely the stimulators and inhibitors of its ATPase activity.  
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Structure and Organization of the Dissertation 
 
The present dissertation is structured in six chapters. 
 
Chapter 1 - Introduction 
 The first chapter deals with the theoretical background that supports the developed 
work, and is sub-divided into 3 subchapters. A brief introduction on P-glycoprotein (P-gp) 
structure and function, on the known P-gp modulators and on the importance of this efflux 
pump in drug pharmacokinetics is presented. Also, this chapter introduces thioxanthones, 
with representative modulators, and highlights the importance of studying chirality issues 
in what concerns to this transporter. 
 
Chapter 2 – Results and Discussion 
 This chapter focuses on the results and discussion of the developed research work, 
being sub-divided into two parts, concerning the synthesis and structure elucidation of the 
synthesized chiral thioxanthones, and their biological evaluation. 
 
Chapter 3 – Experimental  
 The third chapter describes the experimental methodologies used in this work and 
is divided in two parts; the first related with the synthesis, structure elucidation and 
determination of the purity by liquid chromatography, and the second concerning the 
methods used to study the potential modulation of P-pg. 
 
Chapter 4 – Conclusions 
 The fourth chapter focuses on the main conclusions of the developed work, based on 
the proposed objectives. 
 
Chapter 5 – References 
 In this chapter, the references cited throughout the dissertation, as well as the 
browsers used, are presented. 
 
Chapter 6 – Appendixes 
 Chapter 6 is composed by one table, Table 14, which comprises the chemical 
structures of the synthesized chiral thioxanthones. 
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1. ATP-binding cassette transporters  
 
The family of ATP-binding cassette (ABC) transporters is the largest group of 
transmembrane proteins, with 49 transporters identified in humans. These membrane 
transporters are responsible for the active transport of diverse endogenous molecules (e.g., 
lipids, proteins, and products of the metabolism) and xenobiotics (e.g. drugs) out of the cell, 
which is driven by adenosine 5'-triphosphate (ATP) hydrolysis (1, 2).  
Structurally, the transporters belonging to ABC family are similar and typically consist of 
four domains (3-5). They include a pair of ATP-binding domains, also known as nucleotide 
binding domains (NBD), located in the cytoplasm, and two transmembrane domains 
(TMD), normally containing six membrane-spanning α-helices (Figure 1 -topology of a 
prototype ABC protein) (4, 6). 
Two sequence motifs in each NBD, designated Walker A and Walker B, are conserved 
among all ABC transporter superfamily members, as well a third motif, referred to as the 
ABC signature motif (or C motif) (5, 7). These motifs play a vital role in the hydrolysis of 
ATP to adenosine 5'-diphosphate (ADP) + Pi, thus providing the energy for translocation or 
efflux of endobiotic and xenobiotic substrates (3, 7). On the other hand, the hydrophobic 
TMDs are structurally diverse, and have an essential role in recognition and transport of 
various substrates (3, 5). The general structure of the ABC transporters and of these 
domains functions in transporter-mediated translocation of substrates are evidenced in 
Figure 1. 
 
Figure 1 - Structure and mechanisms of efflux of ABC transporters (3). 
The members of this superfamily of transporters are essential for many cells and, 
collectively, play important roles in absorption from the gastrointestinal tract and 
elimination into bile or into urine for a wide range of xenobiotics (1, 3, 8). They also play a 
major role in the disposition and toxicity of xenobiotics since they are critical to maintain 
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the barrier function of numerous tissues, such as the blood–brain barrier (BBB), the blood–
testis barrier, and the maternal–fetal barrier or placenta (8). 
P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance 
proteins (MRPs), are some members of this family of carriers, and are known to have 
enantioselectivity for their substrates (9). Consequently, it is essential to study how these 
pumps participate in the active transport of chiral substrates, in order to better know the 
implications that could result from stereoselectivity (10-12).  
 
1.1. P-glycoprotein (P-gp) 
P-gp is the most studied and better characterized efflux pump belonging to superfamily of 
ABC transporters (13-15). The structure of P-gp complies with the characteristics described 
for the ABC transporters, being a polypeptide made up of two homologous halves that arose 
from gene duplication (16). Each half contains a TMD, formed of six membrane-spanning 
α helices (TMHs), and a NBD, located at the cytoplasmatic face of the membrane (Figure 2) 
(4, 17-19). This 170 kDa protein, also known as ABCB1, is encoded in humans by the 
multidrug resistance genes MDR1 (ABCB1) and MDR3 (ABCB4), but the P-gp expression 
refers, usually, to the ABCB1 isoform (18, 20, 21).  
 
Figure 2 - Topological model of P-glycoprotein (6). 
P-gp was first isolated from colchicine-resistant Chinese hamster ovary cells mutants. 
Consequently, since its discovery, is frequently associated with the development of 
multidrug resistance (MDR) in cancer cells (22). The degree of MDR is strongly correlated 
with changes in the drug permeability, and is largely related with the P-gp expression and 
activity (22, 23). Contrarily to what was initially thought, P-gp expression is not limited to 
cancer cells, being also widely expressed in normal tissues, including the brain, liver, small 
intestine, kidney and lung (7, 14, 24). This efflux pump promotes the outward transport of 
a wide range of structurally unrelated compounds, using the energy from the hydrolysis of 
ATP (16, 25, 26). Thus, it plays important physiological functions, being its primary function 
to protect the cells against toxic xenobiotics and endogenous metabolites (13, 16). 
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Furthermore, the localization of P-gp at the apical side of the cell membrane of tissues and 
organs like colon, kidney and liver (Figure 3), which are usually involved in absorption and 
excretion, suggests that this membrane transporter plays a relevant role in these 
pharmacokinetic processes (13, 27). 
 
Figure 3 - Localization of P-gp on the apical membrane of renal proximal tubule cells (A), the membrane of 
human hepatocytes (B) and the apical membrane of intestinal epithelial cells. Figure adapted from (28). 
A large number of drugs generally used in clinical treatment are modulators of P-gp. As a 
consequence, they can affect the expression/function of this efflux pump and, consequently, 
when administrated, can affect the disposition of various P-gp substrate drugs in normal 
tissues (26). 
 
1.1.1. Mechanisms of drug efflux 
Despite being the better characterized efflux pump, the mechanisms by which this 
membrane transporter combines the ATP hydrolysis with the movement of drugs across the 
plasma membrane is not well fully defined. Several models have been proposed to explain 
the mechanism of P-gp-mediated transport, but just two models, the “hydrophobic vacuum 
cleaner” and the “flippase” models, are in agreement with recent data related with the 
structure of P-gp (15, 21). These two models are illustrated in Figure 4. 
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Figure 4 - Hydrophobic vacuum-cleaner (A) and flippase models of P-gp (B). Adapted from (16) 
The hydrophobic vacuum-cleaner model (Figure 4 – A) was proposed by Higgins and 
Gottesman after performing several studies, which suggested that P-gp may interact with 
its substrates within the membrane and, subsequently, transport them to the extracellular 
medium (29). Therefore, this model described P-gp as a 'vacuum cleaner', which recognizes 
and 'sucks' hydrophobic compounds out of the membrane (29).  
In the “flippase” model (Figure 4 – B), the P-gp substrates are flipped from the inner leaflet 
of the lipid bilayer to either the outer leaflet of the plasma membrane or directly to the 
extracellular medium, where it would passively equilibrate with the aqueous environment 
(29). So, considering this principle, P-gp could be seen as a translocase or ‘flippase’ for 
lipophilic molecules (16). 
These two models suppose a partition of the P-gp substrates into the lipid phase prior to 
interacting with the protein, which may help to explain the extraordinarily broad substrate 
specificity of P-gp. Therefore, the key determinant of specificity seems to be the ability of a 
substrate to properly intercalate into the lipid bilayer, with the subsequent interaction with 
the substrate-binding site being of secondary importance (21). 
 
1.1.2. P-gp substrates  
P-gp substrates constitute a large group of compounds that, though chemically, structurally 
and pharmacologically unrelated, are recognized and transported by P-gp. Among these 
compounds there are many clinically important agents, as anticancer drugs, antibiotics, and 
anti-hypertensives, among many others, some of which are exemplified in Table 1 (15, 16, 
30). 
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Table 1 - Different classes of agents that interact with P-gp (P-gp substrates). 
Therapeutic Class Compounds 
Anticancer 
Anthracyclines: doxorrubicin, daunorubicin, epirubicin, 
mitoxantrone, idarrubicin 
Vinca alkaloids: vincristine, vinblastine, vinorebline, 
vindesine 
Other alkaloids: cepharanthine, homoharringvtonine 
Taxanes: paclitaxel, docetaxel 
Antitumor antibiotics: actinomycin D, mitomycin C 
Antimetabolites: cytarabine, methotrexate, 5-fluorouracil, 
hydroxyurea 
Acridines: amsacrine 
Camptothecins: topotecan, irinotecan 
Epipodophyllotoxins: etoposide, teniposide 
Alkylating agents: chlorambucil, cisplatin 
Tyrosine kinase inhibitors: imatinib mesylate, gefitinib 
Others: tamoxifen, bisantrene 
Antidepressants 
Amitriptyline, nortriptyline, doxepin, escitalopram, 
levomilnacipran, vilazodone 
Analgesic opioids Morphine, pentazocine, fentanyl, loperamide 
Anti-arrhythmics Quinidine, verapamil, digoxin, lidocaine, quinidine 
Anti-emetics Ondansetron, domperidone 
Antiepileptics and 
Anticonvulsants 
Topiramate, phenytoin, carbamazepine, phenobarbital, 
lamotrigine, gabapentin, felbamate 
Antigout agents Colchicine 
Anti-helmintics Ivermectin 
Anti-histaminics H1 Terfenadine, fexofenadine 
Anti-hypertensives 
Reserpine, debrisoquine, celiprolol, losartan, talinolol, 
prazosin 
Antimicrobial agents 
Erythromycin, doxycycline, itraconazole, ketoconazole, 
levofloxacin, rifampicin, sparfloxacin, tetracycline, 
grepafloxacin, clarithromycin, gramicidin A, valinomycin 
Anti-human 
immunodeficiency virus 
(HIV) 
Nelfinavir, ritonavir, saquinavir, amprenavir, indinavir, 
lopinavir 
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Calcium channel blockers Nifedipine, diltiazem, azidopine, nicardipine 
Calmodulin antagonists Trifluoperazine, trans-flupentixol 
Cardiac glycosides Digoxin, digitoxin 
Cholesterol-lowering 
agents 
Lovastantin, simvastantin 
Fluorescent dyes Rhodamine 123, hoechst 33342, calcein acetoxymethylester 
Anti-histaminics H2 Cimetidine, ranitidine 
Immunosuppressive 
agents 
Cyclosporin A, tacrolimus, sirolimus, valspodar 
Linear peptides Leupeptin, pepstatin A 
Muscle relaxant agents Vecuronium 
Neuroleptics Chlorpromazine, phenothiazine 
Steroid hormones 
Aldosterone, corticosterone, dexamethasone, cortisol, 
hydrocortisone, methylprednisolone 
Pesticides Methylparation, endosulfan, paraquat 
Natural products Flavonoids, curcuminoids 
Data was compiled from (5, 6, 16, 21, 31-35). 
Most of these P-gp substrates are weakly amphipathic and relatively hydrophobic and can 
vary in size, structure, and function, ranging from small molecules, such as amino acids and 
some antibiotics, to macromolecules such as polysaccharides and proteins (16, 33). Several 
studies have been undertaken to elucidate the molecular attributes required for interaction 
between this efflux protein and its small substrates, and to identify P-gp substrates or to 
develop better P-gp inhibitors to overcome the problem of MDR (33). The data obtained in 
some of these studies highlighted the lipid solubility, cationic charge, hydrogen bonding 
potential, presence of an amine, molecular weight, size, surface area and the presence of 
aromatic ring structures as being important properties for substrate binding and 
functionality. The presence of an hydrogen bond acceptor (or electron donor) moiety 
(carbonyl, ether, hydroxyl or tertiary amine groups), with a defined spatial separation was 
also considered an important feature, after the screening of structurally diverse P-gp 
substrates using tridimensional modelling (21).  
 
1.1.3. Modulation of P-gp 
Modulators form a group of structurally unrelated compounds, which have the ability of 
modulating P-gp expression or activity, by inhibition or activation (16, 27). Over the years, 
the P-gp modulation has been seen as an important area in drug development, once P-gp 
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interacts with many drugs and is expressed in several organs (6, 7, 36-39). Due to the role 
that P-gp demonstrated to have in MDR, the first studies on this efflux pump were mostly 
focused on its inhibition as a therapeutic option to circumvent MDR (4, 7, 15, 31, 39). 
However, more recent insights showed that P-gp inhibitors might be also useful to modulate 
the general pharmacokinetic behavior of drugs in the organism, revealing special 
importance in case of central nervous system (CNS) active drugs, to allow increasing drugs 
brain penetration (19, 31, 32, 36). Consequently, over the years, several studies were 
developed in order to discover potent and safe P-gp inhibitors, and to better understand 
their mechanisms of inhibition (15, 19, 31, 32, 40-44). 
Furthermore, some recent studies have also focused on the induction/activation of this 
pump, and the use of such inducers/activators to prevent the toxicity mediated by P-gp 
substrates has been proposed as a potential antidotal pathway(6, 20, 25, 45, 46). 
Accordingly, the modulation of P-gp can be applied not only in drug discovery but also in 
drug development, to overcome the limitations of some drugs in clinical use due their 
interaction with P-gp, which affects their clinical effectiveness (6, 26, 44, 45, 47, 48). 
Many modulators have been identified and taking in account their different mechanisms of 
modulating P-gp expression and activity; they were divided in two distinct groups: 
inhibitors and inducers/activators (16, 21).  
 
1.1.3.1 P-gp Inhibitors 
Since the discovery of P-gp, identifying and developing selective and potent P-gp inhibitors 
has been a principal focus area in drug discovery (6, 26, 31, 33, 36, 49-51). The first studies 
focused in the clinical application of P-gp inhibitors in the treating of drug-resistant tumors, 
being MDR clinically important in several diseases. The P-gp inhibitors must be selectively 
targeted to P-gp in non-physiological tissues and must have a high propensity for binding 
to P-gp without inhibiting other ABC transporters (27, 49). According with their potency, 
selectivity and drug-drug interaction potential, the P-gp inhibitors are classified into four 
generations (Table 2) (19). 
Table 2 - Examples of P-gp inhibitors from the four generations. 
 P-gp inhibitors 
First 
generation 
Analgesics: meperidine, pentazocine 
Anesthesics: chloroform, benzyl alcohol, diethyl ether, propofol 
Antibiotics: cefoperazone, cefriaxone, salinomycin, nigericin, erythromycin, 
azithromycin, brefeldin A, befilomycin, clarithromycin, valinomycin 
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Anticancer drugs: tamoxifen, bicalutamide, mitotane, gefitinib, lapatinib,  
erlotinib, lonafarnib, tipifarnib, vinblastine 
Antifungals: itraconazole, ketoconazole, econazole, dihydroptychantol A, 
aureobasidin A 
Anti-histaminics: benzquinamide, azelastine, tesmilifene, astemizole, 
terfenadine 
Anti-inflammatory drugs: zomepirac, indomethacin, curcumin, ibuprofen 
Antidepressants: amoxapine, loxapine, sertraline, paroxetine, fluoxetine 
Antimalarial drugs: quinine 
Antiprotozoal drugs: hycanthone, monensim, metronidazole 
Antiviral drugs: concanamycin A, ritonavir, nelfinavir, saquinavir 
Anxiolytics and sedative-hypnotics: midazolam 
Cardiac/ circulation drugs: amiodarone, propafenone, quinidine, verapamil, 
emopamil, nifedipine, nicardipine, niguldipine, nitrendipine, nimodipine, 
felodipine, isradipine, lomerizine, tetrandrine, mibefradil, diltiazem, 
bepridil, dipyridamole, reserpine, prazosin, doxazosin, carvedilol 
Cholesterol-lowering drugs: atorvastatin 
Immunosuppressants:  
Cyclosporin A, tacrolimus, sirolimus 
Neuroleptics and antipsychotics: trans-flupentixol, perphenazine, 
prochlorpromazine, trifluoperazine, perospirone, haloperidol 
Phosphodiesterase inhibitors: Vardenafil 
Steroid hormones: progesterone, medroxiprogesterone, cortisol, 
methylprednisolone, medroxiprogesterone 17-acetate, mifepristone, 
tirilazad 
Second 
generation 
Dexverapamil, dexniguldipine, cinchonine, hydro-cinchonine, quinine 
homodimer Q2, valspodar (PSC 833), biricodar (VX-853), toremifene, 
dofequidar (MS-209), stipiamide homodimer 
Third 
generation 
Zosuquidar (LY335979), taraquidar (XR9576), elacridar (G120918), 
laniquidar (R101933), ontogen (OC144 093), DP7, PGP-4008, CBT-1 
Fourth 
generation 
Flavonoids: quercetin, tangeretin, nobiletin, sinensetin, baicalein 
heptamethoxyflavone 
Alkaloids: pervilleine F, ellipticine 
Coumarins: cnidiadin, conferone, praeruptorin A, rivulobirin A, DCK 
Cannabinoids 
Taccalonolides 
Diterpenes: jolkinol B, portlanquinol, euphodendroidin D, pepluanin A 
Triterpenes: sipholenone E, uvaol, sipholenol A, oleanolic acid 
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Polyenes: pentadeca-(8,13)-dien-11-yn-2one 
Lignans: schisandrin A, silibinin, nirtetralin 
Surfactants and lipids: pluronic P85, tween-20, triton X-100, cremophor EL, 
poly(ethylene glycol)-300 (PEG-300), Nonidet P40 
Dual ligands: aminated thioxanthones such as 1-[2-(1H-benzimidazol-
2yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one 
Data adapted from (6, 19, 32, 52) 
The first-generation of inhibitors comprises compounds pharmacologically active, which 
were developed and are in clinical use for other indications, but that also demonstrated to 
be P-gp inhibitors (15, 21, 32). This class of compounds includes channel blockers, such as 
verapamil, immunosuppressants, like cyclosporin A, and anti-hypertensives, as reserpine 
and quinidine (15), among other examples described in Table 2. The clinical use of these 
compounds for P-gp inhibition is limited considering the toxicity associated to the high 
concentrations that are needed to inhibit the pump. As a consequence, these compounds 
have low potency and lack of binding affinity for P-gp (15). 
In order to decrease the toxicity of the first-generation of inhibitors, to increase the efficacy 
of the P-gp inhibitory effect and to reduce their main therapeutic activity, the second-
generation was developed. It includes compounds resulting from structural modifications 
of the first-generation members. Therefore, the second-generation of inhibitors includes 
compounds analogues of the first-generation inhibitors, with a higher P-gp affinity (15, 19). 
The P-gp inhibitor valspodar is an example, because it inhibits the P-gp with 5-20-fold 
greater potency than cyclosporin A and does not possess the immunosuppressive effect of 
its structural analogue (21).  
The third-generation of P-gp inhibitors was developed to overcome the limitations of the 
compounds belonging to the first- and second-generations, like the unpredictable drug-
drug interactions and the associated toxicity (15). This class of compounds was developed 
by using quantitative structure-activity relationships (QSAR) and combinatorial chemistry, 
which allowed to design molecules with specific characteristics (19). Zosuquidar 
(LY335979), elacridar (GF120918), laniquidar (R101933), tariquidar (XR9576) and CBT-1 
are some of the most studied inhibitors of third-generation of P-gp inhibitors (15, 19). This 
generation of P-gp inhibitors showed to be the most potent and selective inhibitors, but 
unexpected toxic effects were still observed clinical assays (15, 19, 49). Therefore, the 
development of P-gp inhibitors without toxic effects, in normal tissues, was not 
accomplished within the first three generations of P-gp inhibitors. 
As a result, a fourth-generation of P-gp inhibitors is described as comprising compounds 
extracted from natural origins and their derivatives, surfactants and lipids, 
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peptidomimetics and agents combining transport inhibition with another beneficial 
biological activity (dual ligands) (6). Concerning the dual ligands, several aminated 
thioxanthones were reported as dual inhibitors of cell growth and P-gp, which allowed to 
glimpse a new opportunity for MDR reversal (6). 
 
1.1.3.2. P-gp inducers and activators 
P-gp activity can be increased by a large range of drugs, which can be classified as inducers 
or activators (Table 3) (6, 33). The inducers are compounds that promote an increase in the 
transporter’s expression, which can result in an consequent increase in activity of the pump 
(25). However, to note that P-gp expression and activity may not be proportionally 
increased. For example, exposure of Caco-2 cells to doxorubicin resulted in an increased 
cell surface P-gp expression followed by increases in pump activity, but to a different 
magnitude (20). Also, colchicine increased P-gp protein expression in Caco-2 cells, with no 
significant changes in its activity (53). Therefore, the simultaneous evaluation of both P-gp 
expression and activity in the screening of P-gp inducers is of utmost importance, since an 
increase in the former may not be reflected in an increase in the later. Furthermore, to note 
that P-gp expression should not only be evaluated at the mRNA level but also at the protein 
level. Indeed, Takara et al. reported that P-gp transport function remained unchanged in 
Caco-2 cells exposed to several nonsteroidal anti-inflammatory drugs, in spite of the 
observed increases in MDR1 mRNA levels. Thus, it was proposed that the increased MDR1 
mRNA was not translated into increased P-gp expression (54). 
On the other hand, P-gp activators are compounds that induce a conformational alteration 
when binding to P-gp, thus, stimulating the transport of a substrate on another binding site 
(6). This suggests that the efflux pump contains at least two positively cooperative sites for 
drug binding and transport (6, 25, 45). Moreover, the activation mechanism increases the 
P-gp transport function without interfering with the protein expression levels, unlike what 
happens with P-gp induction, being a quicker process (25). 
Table 3 - Examples of inducers and/or activators of P-gp. 
P-gp inducers and/0r activators 
Ambrisentam Docetaxel Nifedipine 
Amiodarone Doxorrubicin Norathyriol 
Amprenavir Efavirenz Oxycodone 
Avermectin Erythromycin Paclitaxel 
Bosentan -Estradiol Parthenolide 
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Bromocriptine Ethinylestradiol Pentylenetetrazole 
Budesonide Etoposide Phenobarbital 
Cadmium chloride 5-Flurouracil Phenotiazine 
Capsaicin Hydroxyurea Phenytoin 
Carbamazepine Hyperforin Piperine 
Catechin Idarubicin Probenecid 
R-Cetirizine Indinavir Quercetin 
Chlorambucil Insulin Quinidine 
Chrysin Ivermectin Sirolimus 
Ciclesonide Lopinavir 
Reduced rifampicin 
derivative  
Cisplatin LY191401 Reserpine 
Clotrimazole Mangiferin Retinoic acid 
Colchicine Meloxicam Ritonavir 
Coticosterone Methotrexate Rifampicin 
Curcumin Methylprednisolone Ritonavir 
Cyanidin Midazolam Saquinavir 
Cyclosporine A Mitoxantrone Sodium butyrate 
Cytarabine Morphine SR12813 
Daunorubicin Myricetin Tacrolimus 
Dexamethasone Nefazodone Venlafaxine 
Diltiazem Nelfinavir Verapamil 
Digoxin Nevirapine 
Vinblastine 
 
Dimethylsulfoxide Nicardipine  
Data are compiled from (6, 32, 33)  
 
1.1.4. Importance of P-gp modulation in drug pharmacokinetics  
P-gp plays an important role in the absorption, elimination, disposition and toxicity of a 
wide range of compounds, both endobiotics and xenobiotics, since it is responsible by their 
transport across cell membranes. Additionally, it is important to maintain the barrier 
function of numerous tissues, such as the blood–brain barrier, small intestine and placenta 
(8, 27). Considering that many drugs used in clinical treatments are substrates of P-gp, their 
pharmacokinetic processes and, consequently, their effectiveness, can be greatly affected by 
the level of expression and functionality of this pump (16). When a drug that is a P-gp 
substrate is co-administrated with other drug, a P-gp inducer or inhibitor, the 
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pharmacokinetics and bioavailability of the P-gp substrate may be substantially altered 
(33). 
The over-expression of P-gp, caused by a P-gp inducer, on the epithelial cells lining of the 
intestine combined with its substantial role in drug pumping out of these cells, after 
absorption, may generate a poor uptake of the drug in the intestine, thus reducing its oral 
bioavailability, and blocking the delivery of drugs to the brain (16, 33). This is a serious 
problem in drug discovery, especially when developing drugs targeted to the brain, because 
the efficacy of these drugs depends on their ability to cross the blood–brain barrier (16).   
On the other hand, the reduced expression of P-gp can originate a decrease on its activity in 
the intestine, which can lead to dramatically increased drug bioavailability, and 
consequently, toxicity (33). The same can happen if two drugs, that are both P-gp substrates, 
are co-administrated, because they can compete for the transporter and, then, the drugs 
plasmatic levels will be higher for more time (33). Changes in expression of P-gp can also 
interfere with the drugs excretion, which are excreted by renal secretion or active secretion 
into the bile, and have their transport mediated by P-gp (23). Subsequently, the P-gp 
inhibition can result in the inhibition of excretion, what may induce an increased plasma 
concentration, and consequent side effects (23).  
The level of P-gp activity, beyond its importance in drug–drug interactions, plays an 
essential role in the MDR phenomenon. The high expression of P-gp on the surface 
membranes of cancer cells causes high rates of MDR resistance in cancer cells, since P-gp 
transports a wide range of anticancer drugs (26). The mechanism of MDR and the 
importance of P-gp expression in the protection of organisms are shown in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Mechanism of MDR and detoxification by P-gp. Adapted from (55) 
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Curiously, the use of P-gp inhibitors was considered and tested, in several studies, and 
demonstrated to improve the efficiency and pharmacokinetic profile of molecules that 
interact with P-gp, whereas the use of P-gp inducers or activators has been considered as a 
potential mechanism of protection against toxic P-gp substrates (6, 25, 26, 31, 32, 39, 40, 
43, 46, 56). However, as P-gp is expressed in several organs and plays an important role in 
absorption, disposition and excretion of several compounds, the modulators need to 
selectively target P-gp in the target tissues in order to not cause toxicity (32). The great 
impact of P-gp on the pharmacokinetics of its substrate molecules is consistent with the 
strategic physiological expression of P-gp in organs that play key roles in the processes of 
drug absorption and disposition (27). 
 
2. Thioxanthones  
Thioxanthones are a group of S-heterocycles compounds with a dibenzo--thiopyrone 
scaffold (Figure 6) showing interesting biological properties (40, 46, 57).  
 
Figure 6 - Thioxanthonic scaffold. 
Structurally, similar to xanthones, they are an important class of compounds comprising 
synthetic derivatives. The first synthesis of a thioxanthone derivative was reported in 1891 
(58-61). The biological interest in this class of compounds started when lucanthone (Figure 
7 – A) and its metabolite hycanthone (Figure 7 – B) were described for the first time as 
antischistosomal agents (62, 63). Although the drugs lucanthone and hycanthone were 
withdrawn from therapy due to mutagenic side effects, in the 1970’s, the interest in the 
mechanisms of action of these thioxanthones and their derivatives continued (63).  
 
 
 
 
 
 
 
Figure 7 – Structure of (A) lucanthone and (B) hycanthone. 
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Afterwards, hycanthone was also evaluated as antitumor agent in Phase I and II trials 
sponsored by the National Cancer Institute, unleashing a big interest in the study of this 
class of compounds (64). 
Over the years, diverse biological activities of thioxanthonic derivatives were described such 
as P-gp modulation (22, 40, 46), topoisomerase inhibition (65, 66), antitumor activities (43, 
59, 67-73), antibiotic activity (67-70), among others (57, 74, 75). The large number of 
biological activities associated to this class of compounds depends on the nature and/or 
position of the different substituents in the tricyclic scaffold, reason why several 
thioxanthonic derivatives have been synthesized and studied (60). 
 
2.1. Synthesis 
Several different methodologies have been used to synthesize thioxanthones and their 
derivatives (57). The selected method for the synthesis of thioxanthonic derivatives depends 
on the nature and position of the substituents to be introduced on the thioxanthone scaffold 
(76). 
The cyclization of thiosalicylic acid with unsubstituted or corresponding substituted 
aromatic compounds, in a concentrated sulfuric acid medium, is a traditional approach to 
prepare thioxanthone and its derivatives (Scheme 1) (57). However, due to some limitations 
inherent to this one-spot synthesis, such as the requirement of having a thiol and a hydroxyl 
group at the 6 and 6’ position to afford directly the thioxanthone scaffold, other approaches 
involving typically multistep procedures are used in the synthesis of thioxanthones (57). 
 
Scheme 1 
The synthesis via benzophenone derivative, a diarylthioether (phenylthiobenzoic acid) or a 
diarylthioester intermediate (Scheme 2), are some these approaches which are usually used 
to obtain thioxanthonic derivatives  (57, 76). The intramolecular electrophilic cyclization of 
phenylthiobenzoic acid in a concentrated acidic medium (Scheme 2) is the most usual 
method to obtain the thioxanthone scaffold (77, 78). 
 
__________________________________________________________________ Introduction 
17 
 
Scheme 2 
These traditional methods can often result in low yields of the desired product and in a 
mixture of by-products which are difficult to separate by conventional techniques (57). Over 
the years, several reaction conditions were employed in order to optimize the reaction time 
and yield of the synthesis of thioxanthones and thioxanthonic derivatives, which was revised 
by Paiva et al. (57). 
 
2.2.  Thioxanthones as P-gp modulators 
Thioxanthones have been found to exhibit P-gp modulation activities (40, 46, 57, 69). A 
large amount of the studies concerning P-gp modulation were focused on their ability to act 
as P-gp inhibitors, as well as their behavior as antitumor agents (3, 7, 19, 26, 27, 31, 32, 40). 
Since the MDR phenomenon in cancer treatment can be a consequence of the 
overexpression of P-gp in cancer cells, the use of P-gp inhibitors to restore the sensitivity of 
tumor cells to chemotherapeutic agents was seen as a way to overcome MDR in tumors (3, 
32, 39, 57). The combination of P-gp inhibitory properties with antitumor activity in a single 
molecule was hypothesized to lead towards an improved drug response and, thus, a study 
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focused on the possibility of thioxanthonic derivatives with known antitumor activity that 
could also be P-gp inhibitors (40). 
In this study, some P-gp activators/inducers were also discovered (40). These derivatives 
were further investigated and the thioxanthones that promoted an increase the 
transporter’s expression were classified as inducers, while the thioxanthones that increased 
the P-gp transport function without interfering with the protein expression levels were 
classified as activators (25). The P-gp inducers are able to act as an effective intracellular 
protection mechanism since, by increasing the pump expression, they will limit the 
intracellular accumulation of its substrates and, consequently, their toxicity (20, 56). 
Indeed, using the Caco-2 cells in vitro model, these synthetized thioxanthonic derivatives 
were studied in order to evaluate their potential to increase P-gp expression and/or activity, 
and their potential protective effects in Caco-2 cells against the toxicity induced by paraquat 
(PQ), an extremely toxic herbicide that is a P-gp substrate, in an attempt to develop new 
antidotes using this efficient antidotal pathway (46). 
In Table 4 the thioxanthonic derivatives that showed ability to modulate the P-gp activity 
are described. 
Table 4 - Examples of thioxanthone modulators of P-gp. 
Compound 
P-gp 
modulation 
Compound 
P-gp 
modulation 
 
1-methoxy-4-propoxy-9H-
thioxanthen-9-one 
 
Inhibition 
 
1-(isobutylamino)-4-propoxy-9H-
thioxanthen-9-one 
Activation 
 
 
Activation 
 
 
Inhibition 
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1-((3-hydroxypropyl)amino)-4-
propoxy-9H-thioxanthen-9-one 
1-(piperidin-1-yl)-4-propoxy-9H-
thioxanthen-9-one 
 
1-(isopropylamino)-4-propoxy-
9H-thioxanthen-9-one 
 
Activation 
 
3-hydroxy-2-((9-oxo-4-propoxy-
9H-thioxanthen-1-
yl)amino)butanoic acid 
Inhibition 
 
(S)-1-((1-hydroxy-3-
methylbutan-2-yl)amino)-4-
propoxy-9H-thioxanthen-9-one 
 
Activation 
 
1-((2-
(diethylamino)ethyl)amino)-4-
propoxy-9H-thioxanthen-9-one 
Inhibition 
 
1-(4-acetylpiperazin-1-yl)-4-
propoxy-9H-thioxanthen-9-one 
 
Inhibition 
 
1-{[4-
(aminomethyl)benzyl]amino}-4-
propoxy-9H-thioxanthen-9-one 
 
Activation 
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1-{[2-
(phenylamino)ethyl]amino}-4-
propoxy-9H-thioxanthen-9-one 
 
Activation 
 
 N'-(9-oxo-4-propoxy-9H-
thioxanthen-1-yl)pyridine-4-
carbohydrazide 
Inhibition 
 
2-[(9-oxo-4-propoxy-9H-
thioxanthen-1-yl)amino]ethyl 
hydrogen sulfate 
 
Inhibition 
 
1-(5-amino-3,4-
dihydroisoquinolin-2(1H)-yl)-4-
propoxy-9H-thioxanthen-9-one 
Inhibition 
 
1-[(3,5-
dimethoxyphenyl)amino]-4-
hydroxy-9H-thioxanthen-9-one 
 
Inhibition 
1-[2-(1H-benzimidazol-2-
yl)ethanamine]-4-propoxy-9H-
thioxanthen-9-one 
Inhibition 
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1-{[2-(1,3-benzodioxol-5-
yl)ethyl]amino}-4-propoxy-9H-
thioxanthen-9-one 
 
Activation
/ 
Induction 
 
1-[(3,4-dimethoxybenzyl)amino]-
4-propoxy-9H-thioxanthen-9-one 
Activation 
 
1-{[2-(4-
nitrophenyl)ethyl]amino}-4-
propoxy-9H-thioxanthen-9-one 
 
Inhibition 
 
4-hydroxy-1-{[(4-
nitrobenzyl)oxy]amino}-4-
propoxy-9H-thioxanthen-9-one 
Inhibition 
1-[(4-ethoxy-2-
nitrophenyl)amino]-4-hydroxy-
9H-thioxanthen-9-one 
 
Inhibition 
 
1-[(3,4,5-
trimethoxyphenyl)amino]-4-
propoxy-9H-thioxanthen-9-one 
Inhibition 
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1-chloro-9-oxo-9H-thioxanthen-
4-yl acetate 
 
Activation 
 
1-Chloro-4-hydroxy-9H-
thioxanthen-9-one 
Activation
/ 
Induction 
 
4-hydroxy-1-[(3,4,5-
trimethoxyphenyl)amino]-9H-
thioxanthen-9-one 
 
Inhibition 
 
1-[(3-Hydroxypropyl)amino]-4-
propoxy-9H-thioxanthen-9-one 
Activation
/ 
Induction 
 
1-[(2-methylpropyl)amino]-4-
propoxy-9H-thioxanthen-9-one 
Activation
/ 
Induction 
 
1-(propan-2-ylamino)-4-propoxy-
9H-thioxanthen-9-one   
Activation
/ 
Induction 
 
1-(1-((2S,3R,4S,5S,6R)-2-(4-aminophenoxy)-
3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-4-
yl)propoxy)-9H-thioxanthen-9-one 
Inhibition 
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Data compiled from  (40) and (46) 
Several aminated thioxanthones (ATx’s), presented in table 4, were highly effective at 
inhibiting P-gp in a chronic myelogenous leukemia cell line, the K562 cells (40). For 
example, the 1-{[2-(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one 
demonstrated to be the most potent thioxanthone in inhibiting cell growth, as well as a 
potent inhibitor of tumor cell growth (40). Moreover, 1-[(3-hydroxypropyl)amino]-4-
propoxy-9H-thioxanthen-9-one, 1-chloro-4-hydroxy-9H-thioxanthen-9-one, 1-{[2-(1,3-
benzodioxol-5-yl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one, 1-[(2-
methylpropyl)amino]-4-propoxy-9H-thioxanthen-9-one and 1-(propan-2-ylamino)-4-
propoxy-9H-thioxanthen-9-one were the compounds tested as possible antidotes against  
PQ-induced toxicity (46). This last thioxanthonic derivative showed the highest potential in 
inducing P-gp and, consequently, afforded the highest protection against PQ-induced 
toxicity (46).  
Additionally, computational methods were developed in order to explore, in silico, the 
possible binding modes of the thioxanthonic activators and to build a common 
pharmacophore for P-gp activators, which can be used to predict new ligands (46). The 
pharmacophore includes one hydrophobic group, one hydrogen bond acceptor feature and 
one aromatic ring. Moreover, in silico, interactions between thioxanthones and P-gp in the 
presence of PQ suggested that a co-transport mechanism may be operating. Besides the 
thioxanthones, some oxygenated xanthones were also recently reported as P-gp activators, 
by the same group of research (25). 
 
3. Chirality 
Chirality is an important and the most defiant property of stereochemistry (79). In other 
words, it is fundamental in the analysis of static and dynamic characteristics of the three-
dimensional shapes of molecules (80). Considering stereochemistry, it is essential to 
distinguish structural isomerism and stereoisomerism. Structural isomers (or 
constitutional isomers) have the same molecular formula but different connectivity between 
their atoms and functional groups (81). On the other hand, stereoisomers (or spatial 
isomers) are molecules that have the same molecular formula, similar linkages between 
atoms and similar distance of linkages, but differ in spatial or three-dimensional 
arrangement (82). The stereoisomers can be enantiomers or diastereomers (Figure 8). 
When the stereoisomers are mirror images of each other and are nonsuperimposable, they 
are known as enantiomers (80). In contrast, when they are not mirror images they are called 
diastereomers (80).  
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Figure 8 - Example of enantiomers and diastereomers (83). 
The spatial relationship between two enantiomers is classically represented by the 
right and left hands. In Figure 9 the right-handed and left-handed forms of lactic acids are 
presented (84). 
 
Figure 9 - Mirror images of lactic acid (83).  
All compounds that are not overlapping with their own mirror image are called chiral. On 
the other hand, the compounds that do not fit this definition are achiral (82). More often, 
the chiral molecules are characterized by the presence of one asymmetric center known as 
stereogenic center or stereocenter (83). In fact, most chiral organic molecules present 
central chirality, with one or more stereogenic centers, usually tetravalent carbon atoms 
bonded to four different substituents (atoms or groups of atoms). In addition to carbon, 
nitrogen, phosphorus, sulphur, selenium and boron can also produce stereogenic centers 
(85). Chirality can also be originated by a plane or an axis of chirality (86). 
 Enantiomers present identical physical and chemical properties such as boiling 
point and lipophilicity, when they are in an achiral environment (85). However, it is possible 
to distinguish between them when they interact with chiral systems, and by their optical 
activity (82). Concerning this physical property, the enantiomers rotate the plane of 
polarized light in equal amounts but in opposite directions, assigning the symbol (+) or 
letter "d" to the enantiomers that rotate the plane of polarized light in the clockwise 
direction (dextrorotatory) and the symbol (-) or letter "l" to the enantiomers that rotate the 
plane of polarized light in the counterclockwise direction (levorotatory) (83). This is 
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consistent with absence of optical activity in racemic mixtures or racemates, i.e., equimolar 
mixtures of enantiomers (82).  
The optical activity of enantiomers does not depend necessary from their 
configuration, i.e., the spatial arrangement of the substituents around the stereogenic 
center (11). The nomenclature (R)/(S) or Cahn-Ingold-Prelog (CIP) is the most used system 
in the chemical community, to distinguish enantiomers based on their configuration (83), 
setting a framework for an agreed stereochemical pattern (80). This system is based on the 
application of the CIP priority rules, and subsequent assignment of the (R) or (S) 
configuration, taking into account the descending order of higher priority of the groups 
attached to the stereogenic center. So, is attributed the configuration (R) when the order of 
priority of these groups follows the clockwise direction, and the configuration (S) when this 
sequence follows the counterclockwise direction (83). The D/L system developed by Fisher 
in order to describe carbohydrate stereisomers, specifically D- and L-glyceraldehyde, is also 
used for distinguishing enantiomers (83). This system is also commonly used for amino 
acids, which are named by analogy to glyceraldehyde.  
The above mentioned systems are suitable only to determine the relative configuration. X-
ray crystallography and chemical conversion of compounds of known stereochemistry are 
the most commonly used techniques to determine the absolute configuration (83). 
 
3.1. Enantioselectivity 
The human organism is a chiral environment since proteins are constituted by L-amino 
acids, while the carbohydrates are D-isomers of natural sugars (87, 88). Accordingly, the 
biomacromolecules such as receptors and enzymes, comprising these chiral units, are able 
to discriminate between the enantiomers, both in pharmacokinetic and pharmacodynamic 
processes (89). The enantiodiscrimination by biological systems is clinically important 
when the pharmacological and toxicological effects are significantly different between 
enantiomeric drugs (90). In such cases, one enantiomer can be responsible for the 
therapeutic activity while the other enantiomer can be inactive, possess lower activity of 
interest, or can be an antagonist of the active enantiomer, or has a different activity that 
could be desirable or undesirable (91).  Some examples of well-known stereoselective 
responses concerning chiral drugs are presented in Table 5. 
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Table 5 - Examples of stereoselective responses in human concerning chiral drugs. 
Drug or group of 
drugs 
Enantiomer Stereoselective response 
Thalidomide 
(S)-(-) 
Teratogenic, inhibits the release of TNF- 
from stimulated mononuclear blood cells 
(R)-(+) Sedative 
-Blockers (S)-(-) 
100 Times higher antagonistic effect on -
adrenergic receptors than 
(R)-(+)- enantiomer 
Barbiturics 
(S)-(-) Hypnotic and/or sedative 
(R)-(+) Inactive or excitatory 
-Adrenergic receptor 
antagonists 
(R)-(-) 
Responsible for the bronchodilatory 
pharmacological effect 
(S)-(+) No pharmacological effects 
Citalopram 
(R)-(-) 
Non active and antagonizes the effect of    
(S)-(+)-enantiomer 
(S)-(+) 
Pharmacologically active as a selective 
serotonin reuptake inhibitor 
1,4-Dihydropyridines 
(S)-(-) 
Calcium channel agonist, resulting in 
positive inotropic and vasoconstriction 
responses 
(R)-(+) 
Calcium channel antagonist, resulting in 
vasodilation and, at high doses, negative 
inotropic effects 
Pencillamine 
(S)-(-) Anti-arthritic pharmacological action 
(R)-(+) Toxic (mutagenic) 
Ibuprofen 
(S)-(-) 
110 times more potent at COX 1 and 2 
inhibition than (R)-(+) 
(R)-(+) Acts as a pro-drug through chiral inversion 
Data adapted of (11). 
Also in pharmacokinetics, several examples of stereoselectivity are reported concern the 
absorption, distribution, metabolism and excretion (ADME) of drugs (12).  
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The stereoselectivity in metabolism is considered the primary factor responsible for the 
differences observed in enantioselective drug disposition. This is observed since the 
stereoselectivity in metabolism results, many times, in the metabolism of enantiomers at 
different rates and/or different routes, thus yielding alternative products (10). However, 
changes in the absorption and distribution of chiral compounds caused, for example, by 
stereoselectivity for binding proteins and transporters, as P-gp, can cause also important 
changes in the free fraction of drug in the plasma, in the volume of distribution, in the time 
half-life and the clearance, among others, which can induce toxicity or adverse effects 
associated to drugs (10). In the excretion, stereoselectivity may arise as a result of selectivity 
in protein binding and can, consequently, cause changes in glomerular filtration and passive 
reabsorption, in the active secretion or in the reabsorption. However, in the majority of 
cases, the selectivity is relatively modest (10). 
As a consequence,  the use of racemic mixtures typically results in stereoselective drug 
disposition and may also contribute to the toxicity or adverse effects associated with drugs 
(89). In fact, the use of stereochemically pure drugs is normally clinically advantageous 
(90), since it enables a reduction of the total administered dose, enhances the therapeutic 
window, reduces the intersubjective variability and confers a more precise estimation of 
dose–response relationships, among other advantages (91). 
For these reasons, is essential to study the enantioselectivity in the development of new 
drugs (86), because the administration of chiral drugs in racemic form might induce toxicity 
and, in more harsh cases, may be the source of diseases with high mortality rate, as for 
example cancer (82). 
 
3.2. Importance of chirality in P-gp modulation 
The enantiomeric transport is a complex process and depends of different factors, namely 
enantiomer–enantiomer interactions, interspecies or tissue-specific differences, the 
concentration-dependent stereoselectivity and opposite stereoselectivity in modulation of 
drug transporters by the enantiomer (9). The stereoselective binding strength of carriers for 
drugs can be species- or tissue-specific, concentration-dependent and transporter family 
member-dependent (10). 
For instance, stereoselectivity of P-gp may be a result in differences in the transport of 
enantiomers (9). A study with pioglitazone, a P-gp substrate, showed that the use of (+)-
pioglitazone in enantiomeric pure form may improve clinical efficacy of the drug, because 
the (+)-pioglitazone levels were clearly higher than (-)-pioglitazone levels in the brains of 
mice dosed with racemic pioglitazone. The opposite trend was observed in the plasma (92). 
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The higher presence of (+)-pioglitazone in the brain suggests that can be more distributed 
to the brain and/or be retained for longer duration in the brain. Thus, the lower presence of 
(+)-pioglitazone in plasma may translate to fewer undesirable drug effects or drug-induced 
toxicity in peripheral tissue organs (92). 
Furthermore, P-gp can be modulated in a different way by enantiomers (Zhou 2014). When 
the chiral drugs are P-gp modulators, one isomer can induce the activity of P-gp while its 
enantiomeric pair can inhibit the activity of the pump (23, 93). An example of this 
enantioselectivity was observed for mefloquine, a drug used in the prevention and treatment 
of malaria: (11R,12S)-(+)-mefloquine presents a much higher human brain penetration than 
(11S,12R)-(-)-mefloquine (94). The higher brain penetration of the (11R,12S)-(+)-
enantiomer in humans, when compared to its antipode, was explained by the fact of 
mefloquine being a P-gp substrate (94). Moreover, the enantioselective inhibition of P-gp 
by the (-)-isomer of mefloquine was hypothesized to affect the transport of other P-gp 
substrates, such as cyclosporin and vinblastine (Figure 10). 
 
Figure 10 - Enantioselectivity of P-gp by mefloquine enantiomers. 
Another interesting example of P-gp enantioselectivity was described for the H1 anti-
histaminic cetirizine (Figure 11) (93). The (R)-cetirizine upregulates P-gp expression, while 
(S)-cetirizine down-regulates it (82, 93). Moreover, the (R)-enantiomer of cetirizine has 
approximately thirty-fold higher affinity to the human histamine H1-receptors, when 
compared to the (S)-enantiomer (95). 
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Figure 11 - Structure of cetirizine. The asterisk (*) indicates the stereogenic center  
 
The enantioselective modulation of P-gp can also be concentration-dependent (9). This is 
the case of clausenamide (CLA), a candidate drug being currently developed to treat 
memory impairment in neurodegenerative diseases (96), being the isomer (3S,4R,5R,6S)-
clausenamide [(−)-CLA] the eutomer (97). Results of a study performed in cells expressing 
P-gp, suggested that (−)-CLA could be a P-gp inhibitor while (+)-CLA could be an inducer 
of P-gp with concentration-dependent biphasic effects (97). Consequently, CLA shows 
stereoselective regulation of P-gp activity and possible drug—drug interactions when 
combined with other P-gp substrate drugs (97). These drug-drug interactions P-gp 
mediated may contribute for inefficacy or toxicity of drugs, depending if the modulators 
induce or inhibit the P-gp expression and of the degree of change in the activity of pump 
(23, 93).  
Thus, chirality can have a considerable effect on any barrier, in vivo, being an important 
role not only on the absorption of drugs but also in their distribution and elimination issue 
in P-gp modulation (10, 12). 
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PART I - CHEMISTRY 
 
1.1. Synthesis of thioxanthonic derivatives 
Thioxanthones are a class of compounds with interesting biological properties and, recently, 
have been described as P-glycoprotein (P-gp) modulators (19, 40, 46). Additionally, the 
modulation of P-gp by this class of compounds has been seen as a possible  therapeutic 
strategy (6), for example against PQ cytotoxicity (25, 46). Moreover, once the chirality is 
considered as one of the major topics  in the development of new drugs (89), it is essential 
to understand the effects that the enantioselectivity may have in modulation of P-gp by 
thioxanthonic derivatives. 
Accordingly, our aim was the synthesis and characterization of a small library of new 
enantiomeric pairs of thioxanthonic derivatives, using 1-chloro-4-propoxy-9H-
thioxanthen-9-one as chemical substrate (Tx) (Figure 12).  
 
 Figure 12 – Structure of the thioxanthone chemical substrate (Tx). 
The new chiral thioxanthonic derivatives (ATx’s 1-8) were synthesized by Ullmann cross 
coupling reaction between the thioxanthone derivative 1-chloro-4-propoxy-9H-
thioxanthen-9-one (Tx) with eight enantiomerically pure building blocks (A 9-16) (Figure 
13).  
 
Figure 13 - General scheme of the synthesis of chiral thioxanthonic derivatives. 
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The conditions used were based on previous described procedures (98). All the synthesis 
was performed in alkaline medium, in a closed vessel, mixing the chiral amino alcohols (A 
9-16), in excess, with 1-chloro-4-propoxy-9H-thioxanthen-9-one (Tx), CuI in catalytic 
amounts (10% equiv.) in methanol. The reactions were carried out at 100 °C for 48 hours, 
without stirring.   
The structures of the synthesized thioxanthonic derivatives ATx 1-8 and the 
enantiomerically pure amino alcohols A 9-16 are shown in Figure 14. 
 
Figure 14 - Structures of the amino alcohols used as building blocks and the correspondent aminated 
thioxanthones. 
The thioxanthone chemical substrate (Tx) and all the enantiomerically pure building blocks 
are commercially available, and were chosen based on a previous work (40) in which 
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thioxanthonic derivatives comprising the same thioxanthone pattern of substitution, i.e., a 
propoxy group at position 4 and an chiral amine at position 1 afforded the most interesting 
results on P-pg modulation. Moreover, in the same study aliphatic amino alcohols were the 
most promising activators.  Therefore, the four enantiomeric pairs represented in Figure 14 
were selected for this work. All the amino alcohols, namely (S)-(+)-2-amino-1-propanol (9), 
(R)-(-)-2-amino-1-propanol (10), (S)-(+)-1-amino-2-propanol (11), (R)-(-)-1-amino-2-
propanol (12), (S)-(+)-leucinol (13), (R)-(-)-leucinol (14), (S)-(+)-valinol (15) and (R)-(-)-
valinol (16), were available in enantiomerically pure form, and no tendency towards 
racemization or enantiomeric interconversion is expected. 
The reactions were accomplished by a nucleophilic aromatic substitution of the chloride on 
position C-1 of the thioxanthone scaffold by the enantiomerically pure building blocks, 
affording the desirable chiral thioxanthone (ATx’s 1-8). The main product formed 
corresponded to the C-N coupling. In all cases, a secondary product, a methoxylated 
derivative of the thioxanthone (TxOMe) (Figure 13), corresponding to the competition of C-
O cross coupling, was observed and identified by thin-layer chromatography (TLC) by the 
comparison with a standard previously synthesized and characterized, using the same 
reaction conditions (98). Besides TxOMe, other byproducts were detected in vestigial 
amounts, so they were not isolated for identified. 
The reactions progress was monitored by TLC analysis using chloroform/acetone, 9.7:0.3 
(v/v) as mobile phase and observed under ultraviolet (UV) light at 254 and 365 nm. 
The work-up of the reactions followed a general procedure. After 48 hours, the reaction 
mixture was first filtered in order to eliminate the CuI. By chemical liquid-liquid extraction 
with HCl solution most of the acidic/neutral organic impurities were removed in the organic 
layer. Following, the amines were regenerated with NaOH, extracted and the extract was 
further subjected to a solid phase extraction (SPE) with a cation exchange cartridge to 
eliminate remaining impurities (TxOMe and other compounds with similar 
chromatographic behaviour). 
This sequence of purifications was successful for the purification of thioxanthonic 
derivatives 4, 5, 6 and 7. However, they were insufficient to isolate pure aminated 
thioxanthones 1, 2, 3 and 8. For thioxanthonic derivatives 3 and 8, a further purification 
process by crystallization from chlorophorm/diethyl ether was needed. Thioxanthones 1 
and 2 were further purified by flash chromatography from their remaining precursors and 
following by crystallization from chlorophorm/diethyl ether.  
As expected, this synthetic approach yielded the desirable products, as occurred for similar 
compounds in a previous work (40, 98). However, the obtained isolated yields were low 
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ranging from 2 to 24 % (Table 6), even in the presence of K2CO3 that provided an alkaline 
media favorable to reaction. This may be a consequence of the formation of the secondary 
product TxOMe (Figure 13). Despite the low yields, these reactions afforded enough 
quantity of the desired four enantiomeric pairs of chiral thioxanthonic derivatives for 
characterization and further biological activity studies. 
Table 6 – Yields obtained for each chiral thioxanthone derivative. 
Chiral thioxanthonic 
derivatives 
Yield (%) 
ATx 1 (1) 1.97 
ATx 2 (2) 5.91 
ATx 3 (3) 7.86 
ATx 4 (4) 23.62 
ATx 5 (5) 19.59 
ATx 6 (6) 10.40 
ATx 7 (7) 10.12 
ATx 8 (8) 10.24 
 
The purity of each synthesized chiral thioxanthones was determined by high performance 
liquid chromatography with diode-array detection (HPLC–DAD) analysis. Figure 15 
illustrates a representative chromatogram obtained for ATx 8 (8).  
 
Figure 15 - HPLC chromatogram of ATx 8 (8). [= 254nm, C18, isocratic elution of methanol and water 
(80:20 v/v) basified with triethylamine (0.5 %) at a constant flow rate of 1.0 mL/min]. 
All tested compounds presented a purity of at least 95 %, as described in Table 7.   
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Table 7 – HPLC purity and melting point (m.p.) of all synthesized compounds. 
Compound Purity (%) m.p. (0C) Compound Purity (%) m.p. (0C) 
ATx 1 (1) 95.5 116 -118 ATx 5 (5)  98.6 82 - 85 
ATx 2 (2) 97.5 118 -120 ATx 6 (6) 98.6 80 - 82 
ATx 3 (3) 96.9 149 -152 ATx 7 (7) 97.8 100 - 102 
ATx 4 (4) 96.4 148 -150 ATx 8 (8) 98.4 102 - 104 
As expected, the melting points were similar for both enantiomers of each enantiomeric pair 
(85). 
 
1.2. Structure Elucidation 
The structure elucidation of all new thioxanthonic derivatives (ATx’s 1-8) was established 
by spectroscopic methods: infrared (IR), 1H and 13C nuclear magnetic resonance (NMR), 
and bidimentional heteronuclear single quantum correlation (HSQC) and heteronuclear 
multiple bond correlation (HMBC).  Since these determinations were performed in achiral 
environments, no significant differences were noted for each pair of enantiomers obtained, 
as expected.  
The IR data of the synthesized thioxanthonic derivatives are presented in Table 8.  
Table 8 - IR data of the synthesized thioxanthonic derivatives. 
Compound Bond Vmax (cm-1) 
ATx 1 (1) 
O-H 3419 
N-H 3270 
C-H 2962, 2925, 2873 
C=O 1618 
C-C 1568, 1507, 1435 
C-N 1252 
C-O 1225, 1070 
ATx 2 (2) 
O-H 3447 
N-H 3282 
C-H 2963, 2927, 2874 
C=O 1611 
C-C 1595, 1569, 1506, 1436 
C-N 1252 
C-O 1226, 1072 
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ATx 3 (3) 
OH 3460 
N-H 3320 
C-H 2965, 2933, 2875 
C=O 1607 
C-C 1566, 1556, 1501, 1450 
C-N 1249 
C-O 1227, 1060 
ATx 4 (4) 
O-H 3460 
N-H 3323 
C-H 2966, 2932, 2875 
C=O 1606 
C-C 1566, 1556, 1501, 1451 
C-N 1249 
C-O 1227, 1060 
ATx 5 (5) 
O-H 3457 
N-H 3290 
C-H 2955, 2923, 2870 
C=O 1613 
C-C 1595, 1566, 1505, 1435 
C-N 1265 
C-O 1224, 1067 
ATx 6 (6) 
O-H 3459 
N-H 3291 
C-H 2954, 2925, 2871 
C=O 1613 
C-C 1595, 1566, 1505, 1435 
C-N 1266 
C-O 1224, 1072 
ATx 7 (7) 
O-H 3385 
N-H 3256 
C-H 2960, 2926, 2873 
C=O 1614 
C-C  1569, 1514, 1463, 1434 
C-N 1249 
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C-O 1225, 1070 
ATx 8 (8) 
O-H 3423 
N-H 3272 
C-H 2959, 2925, 2872 
C=O 1611 
C-C 1570, 1511, 1463, 1435 
C-N 1251 
C-O 1226, 1068 
 
As expected, the IR spectra of the eight thioxanthonic derivatives showed the presence of 
absorptions bands corresponding to N-H bond (3270-3323 cm-1) and to O-H bond (3385 - 
3460 cm-1), which allowed to hypothesize the binding of the chiral building blocks to the 
thioxanthone scaffold by an amine group. Moreover, considering the thioxanthonic scaffold, 
the IR data indicate the presence of an absorption band corresponding to C=O (1606 - 1628 
cm-1). It is also important to highlighted the presence of two absorption bands 
corresponding to C-O (1060-1072 and 1224-1227 cm-1), associated with the carbonyl group 
of carbon 9 and to ether group of aliphatic chain of carbon 4, respectively.  Additional bands 
corresponding to the aromatic carbons (C-C bonds: 1434 – 1595 cm-1), typical of 
thioxanthonic compounds, could be found. 
The 1H and 13C NMR data for aminated thioxanthones 1-8 are presented in Tables 9 - 12.  
All the synthesised thioxanthonic derivatives showed similar NMR profiles with respect to 
the six aromatic protons of the thioxanthonic scaffold and to the protons of the propoxy 
group, with similar chemical shifts and coupling constants as the building block values. 
Regarding the 1H NMR spectra (Table 9 and 10), the signals corresponding to the six 
aromatic protons, namely H-2, H3, H-5, H-6, H-7, and H-8, present a range of chemical 
shifts   between 6.73 and 8.56 ppm. The highest chemical shift value for proton H-8 is due 
to the magnetic anisotropy of carbonyl group (C-9) that deshields this proton. 
Concerning the signals of the aliphatic chain at C-4, the chemical shifts of H-a, H-b and H-
c were comprised between 1.11 and 4.10 ppm, with small variations between the different 
compounds. 
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Table 9 - 1H NMR data for ATx 1 (1), ATx 2 (2), ATx 3 (3) and ATx 4 (4). 
 
    
ATx 1 (1) ATx 2 (2) ATx 3 (3) ATx 4 (4) 
δH (ppm) 
1’ 3.81, 1H, m 3.78, 1H, m 3.30, 2H, m 3.29, 2H, m 
2’ 1.32, 3H, d,  
J = 6.2 Hz 
1.33, 3H, d,  
J = 6.3 Hz 
4.26, 1H, m 4.22, 1H, m 
CH2OH /CH3 3.81, 2H, m 3.78, 2H, m 
1.35, 3H, d,  
J = 6.3 Hz 
1.35, 3H, d,  
J = 6.3 Hz 
2 6.85, 1H, d,  
J = 9.0 Hz 
6.82, 1H, d,  
J = 9.1 Hz 
6.78, 1H, d,  
J = 9.0 Hz 
6.73, 1H, d,  
J = 9.0 Hz 
3 7.13, 1H, d,  
J = 9.0 Hz 
7.13, 1H, d,  
J = 9.1 Hz 
7.13, 1H, d,  
J = 9.0 Hz 
7.12, 1H, d, 
J = 9.0 Hz 
5 7.56, 1H, m 7.56, 1H, m 7.56, 1H, m 7.50, 1H, m 
6 7.56, 1H, m 7.56, 1H, m 7.56, 1H, m 7.50, 1H, m 
7 7.43, 1H, m 7.42, 1H, m 7.42, 1H, m 7.41, 1H, m 
8 8.50, 1H, d,  
J = 8.0 Hz 
8.50, 1H, d,  
J = 8.1 Hz 
8.52, 1H, d,  
J = 8.1 Hz 
8.51, 1H, d,  
J = 8.0 Hz 
a 4.03, 2H, t,  
J = 6.5 Hz 
4.04, 2H, t,  
J = 6.5 Hz 
4.03, 2H, t,  
J = 6.5 Hz 
4.03, 2H, t,  
J = 6.4 Hz 
b 1.90, 2H, m 1.90, 2H, m 1.90, 2H, m 1.90, 2H, m 
c 1.12, 3H, t,  
J = 7.4 Hz 
1.11, 3H, m 
1.12, 3H, t,  
J = 7.4 Hz 
1.12, 3H, t,  
J = 7.4 Hz 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference.  
The 1H-NMR spectrum of both enantiomers ATx’s 1 and 2 (1 and 2) and ATx’s 3 and 4 (3 
and 4) exhibited characteristic signals for the different protons of the aminated chain, 
however the signal corresponding to the NH of the amine could not be observed. The signals 
corresponding to the aminated chain of ATx 1 (1) appear at H-1’: 3.81, CH2OH: 3.81, and H-
2’: 1.32 ppm. As expected the signals of ATx 2 (2) are similar.  
In the case of the 1H NMR spectrum of ATx 3 (3) and ATx 4 (4), the signals corresponding 
to chiral moieties arise at H-1': 3.30, H-2': 4.26 and CH3: 1.35 ppm. 
The 1H NMR data of ATx 5 (5), ATx 6 (6), ATx 7 (7) and ATx 8 (8) are described in Table 
10. 
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Table 10 - 1H NMR data* for ATx 5 (5), ATx 6 (6), ATx 7 (7) and ATx 8 (8). 
 
  
  
ATx 5 (5) ATx 6 (6) ATx 7 (7) ATx 8 (8) 
δH (ppm) 
1’ 
3.88, 1H, dd,  
J = 3.12 and  
J = 3.03 Hz 
3.85, 1H, dd,  
J = 3.78 and  
J =3.27 Hz 
3.53, 1H, m 3.50, 1H, m 
2’ 
1.57, 2H, t,  
J = 6.9 Hz 
1.57, 2H, t,  
J = 6.9 Hz 
2.08, 1H, m 2.10, 1H, m 
3’ 1.78, 1H, m 1.76, 1H, m - - 
4’a / 3’a 
0.94, 3H, d,  
J = 6.5 Hz 
0.96, 3H, d,  
J = 6.5 Hz 
1.05, 3H, d,  
J = 6.9 Hz 
1.02, 3H, d,  
J = 6.9 Hz 
4’b / 3’b 
0.89, 3H, d,  
J = 6.5 Hz 
0.89, 3H, d,  
J = 6.5 Hz 
0.87, 3H, d,  
J = 6.9 Hz 
0.98, 3H, d,  
J = 6.9 Hz 
CH2OH 3.71, 2H, m 3.72, 2H, m 3.86, 2H, m 3.90, 2H, m 
2 
6.93, 1H, d,  
J = 9.0 Hz 
6.86, 1H, d,  
J = 9.1 Hz 
7.07, 1H, d,  
J = 9.1 Hz 
7.17, 1H, d, 
 J = 8.9 Hz 
3 
7.13, 1H, d,  
J = 9.0 Hz 
7.12, 1H, d, 
 J = 9.1 Hz 
7.14, 1H, d,  
J = 9.1 Hz 
7.34, 1H, d,  
J = 8.9 Hz 
5 7.57, 1H, m 7.55, 1H, m 7.59, 1H, m 7.64, 1H, m 
6 7.57, 1H, m 7.55, 1H, m 7.59, 1H, m 7.64, 1H, m 
7 7.42, 1H, m 7.42, 1H, m 7.45, 1H, m 7.49, 1H, m 
8 
8.51, 1H, d,  
J = 8.1 Hz 
8.51, 1H, d,  
J = 8.1 Hz 
8.54, 1H, d,  
J = 8.0 Hz 
8.56, 1H, d, 
 J = 8.0 Hz 
a 
4.04, 2H, t,  
J = 6.5 Hz 
4.03, 2H, t,  
J = 6.5 Hz 
4.06, 2H, t,  
J = 6.4 Hz 
4.10, 2H, t, 
J = 6.4 Hz 
b 1.85, 2H, m 1.83, 2H, m 1.91, 2H, m 1.91, 2H, m 
c 
1.12, 3H, t,  
J = 7.4 Hz 
1.12, 3H, t,  
J = 7.4 Hz 
1.12, 3H, m 1.14, 3H, m 
*Values in ppm (δH) relative to (CH3)4Si as an internal reference.  
The most deshielded protons of the chiral moieties of both enantiomers Tx 5 and 6 (5 and 
6) are close to the amine ((H-1’: 3.88 and 3.85 ppm) and alcohol groups (H-CH2OH: 3.71 and 
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3.72ppm). The four signals remaining that characterize the chiral moieties of these 
compounds, showed values of  ranging from 0.89 to 3.88 ppm. 
The 1H RMN data of ATx 7 (7) and ATx 8 (8) showed the presence of five signal 
corresponding to the chiral moiety. The most deshielded protons are close to the the OH 
(H-CH2OH: 3.86 and 3.90 ppm), and NH groups (H-C1’: 3.53 and 3.50 ppm). 
The 13C NMR data of all chiral thioxanthonic derivatives (Table 11 and 12) showed the 
presence of one signal with the highest chemical shift value corresponding to the carbon of 
carbonyl group (δC-9: 183.46 - 183.65 ppm) of the thioxanthone scaffold. Moreover, signals 
corresponding to the carbons linked to the ether chain (δC-4: 145.00 – 147.74 ppm) and 
amine groups (δC-1: 141.53 – 144.02 ppm) are also present. The lowest values shifts (δC-a-C-c: 
10.14 - 72.52 ppm) correspond to the three carbons of the propoxy groups. The signals 
corresponding to the remaining ten carbons of the thioxanthone scaffold presented values 
ranging from 108.42 to 137.16 ppm.  
Table 11 - 13C NMR data* for ATx 1 (1), ATx 2 (2), ATx 3 (3) and ATx 4 (4). 
 
    
ATx 1 (1) ATx 2 (2) ATx 3 (3) ATx 4 (4) 
δC (ppm) 
1’ 51.91 51.55 54.12 52.07 
2’ 16.86 17.00 65.58 66.11 
CH2OH / CH3 65.96 66.04 20.97 21.02 
1 144.02 144.00 144.01 143.91 
2 109.80 109.02 111.83 108.42 
3 119.12 119.35 117.94 119.25 
4 146.50 146.80 146.18 147.48 
4a 129.85 129.91 129.54 129.92 
5 125.20 125.20 126.10 125.95 
6 136.85 136.82 136.98 136.81 
7 125.98 125.97 126.32 126.02 
8 126.08 126.05 127.19 129.26 
8a 131.92 131.87 133.27 131.83 
9 183.55 183.56 183.46 183.46 
9a 129.24 129.22 129.43 129.85 
10a 114.10 114.00 115.36 113.95 
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a 72.48 72.52 72.31 72.47 
b 22.66 22.70 22.74 22.85 
c 10.71 10.71 14.15 10.71 
*Values in ppm (δC) relative to (CH3)4Si as an internal reference. 
The presence of the chiral moieties in thioxanthones 1-8 were evidenced, in 13C RMN data, 
by the presence of the signals corresponding to C-1’, C-2' and C-CH2OH/CH3. 
Table 12 - 13C NMR data* for ATx 5 (5), ATx 6 (6), ATx 7 (7) and ATx 8 (8). 
 
  
  
ATx 5 (5) ATx 6 (6) ATx 7 (7) ATx 8 (8) 
δC (ppm) 
1’ 64.62 64.87 63.93 67.02 
2’ 40.44 40.71 28.83 28.87 
3’ 24.90 24.92 - - 
4’a / 3’a 22.86 22.96 18.53 19.31 
4’b / 3’b 22.83 22.86 18.41 18.58 
CH2OH 55.01 54.35 61.56 61.17 
1 142.80 142.80 142.8 141.53 
2 111.02 108.80 111.6 115.38 
3 119.05 119.42 117.82 117.12 
4 145.00 145.00 145.0 147.74 
4a 129.97 129.93 129.53 130.43  
5 126.00 125.97 125.51 126.19 
6 136.7 136.82 136.43 137.16 
7 126.11 126.03 125.70 126.52 
8 129.28 128.80 128.84 129.21 
8a 131.98 131.87 131.66 132.60 
9 183.61 183.61 183.43 183.65 
9a 129.83 129.24 129.03 129.52 
10a 114.43 113.94 114.71 116.69 
a 72.45 72.49 71.80 72.19 
b 22.61 22.55 22.21 22.65 
c 10.71 10.71 10.14 10.69 
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*Values in ppm (δC) relative to (CH3)4Si as an internal reference. 
The 13C NMR data of ATx 5 (5) and ATx 6 (6) showed the presence of six signals 
corresponding to the chiral moiety with similar values (C-1’: 64.62, C-2’:40.44, C-3’: 24.90, 
C-4’a: 22.86C-4’b: 22.8 and C-CH2OH: 55.01 ppm for ATx 5 (5)). 
 In the case of both enantiomers of ATx 7 and 8, it should be noted the presence of five 
signals corresponding to chiral moieties (C-1’: 63.93, C-2’:28.83 and 28.87, C-3’a: 18.53, C-
3’b: 18.41 and C-CH2OH: 61.56 ppm for ATx 7 (7); ATx 8 (8) presented similar signals). 
The 13C NMR assignments were made by HSQC and HMBC experiments and by comparison 
with assignments of similar molecules. The HMBC data were important to deduce the 
chemical shifts of quaternary carbons and confirm the C-N coupling product. 
The main connectivity of HMBC for ATx 2 (2) and ATx 4 (4) can be seen in Figure 16.  
 
 
 
 
 
 
The connectivities of HMBC for ATx 6 (6) and ATx 7 (7) are presented in Figure 17. 
 
 
 
 
 
 
For example, the formation of the amine linkage at the carbon 1 with the amino alcohol 
building block to afford ATx 4 could be confirmed by HMBC by the correlation between the 
Figure 16 - Correlations between carbons and protons in HMBC spectrum of ATx 2 and ATx 4. 
Figure 17 - Correlations between carbons and protons in HMBC spectrum of ATx 6 and ATx 7. 
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H-1' and carbons C-1 and C-2' (Figure 16). The data provided by HMBC spectrum are 
consistent with the structure of the ATx 6 and ATx 7. 
Considering that the synthesized compounds are chiral, the determination of their specific 
rotation was also performed. The results of measured rotation obtained with a polarimeter 
and the specific rotation are present in Table 13. 
Table 13 - Specific rotation data for the synthesized thioxanthonic derivatives. 
Compound C (g/mL) * α (0) 
[∝]𝑫
𝟐𝟓℃ 
(0) 
Compound C (g/mL) * α (0) 
[∝]𝑫
𝟐𝟓℃ 
(0) 
ATx1 (1) 3.4 x 10−3 +0.38 +112 ATx 5 (5) 6.75 x 10−3 -0.46 -68 
ATx 2 (2) 3.4 x 10−3 -0.38 -112 ATx 6 (6) 6.75 x 10−3 +0.38 +56 
ATx 3 (3) 6.67 x 10−3 -0.08 -12 ATx 7 (7) 6.80 x 10−3 -0.18 -26 
ATx 4 (4) 6.67 x 10−3 +0.08 +12 ATx 8 (8) 6.80 x 10−3 +0.18 +26 
* Dichloromethane  
As expected, both enantiomers of the same enantiomeric pair of thioxanthonic derivatives 
(ATx’s 1-8) presented similar absolute values of specific rotation but with opposite signals. 
These results confirmed that the synthesis occurred without racemization, and allowed to 
stablish which of the enantiomers is the dextrorotatory and the levorotatory. 
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PART II - BIOLOGICAL ACTIVITY 
 
2.1. Cytotoxicity Assay 
Thioxanthones cytotoxicity (ATx 1-8) was evaluated by the NR uptake assay, in order to 
select a noncytotoxic working concentration to be used in the subsequent studies that aim 
to evaluate their potential to induce and/or activate P-gp. After 24 hours of incubation, 
significant cytotoxicity was observed for the 50 μM concentration of aminated 
thioxanthones 1, 2, 6, 7 and 8 (Figure 18). For the other tested aminated thioxanthones 
(ATx’s 3, 4, and 5), no cytotoxicity was observed after 24 hours of incubation within the 
tested concentration range (0-50 μM). Therefore, ATx’s effect on P-gp expression and 
activity was further evaluated using a noncytotoxic concentration of 20 M. 
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Figure 18 - Aminated thioxanthones ATx 1 - ATx 8 
(0 – 50 μM) cytotoxicity in Caco-2 cells evaluated by the Neutral Red uptake assay, 24 hours after exposure. 
Results are presented as mean ±  standard error mean (SEM) from at least 5 independent experiments 
(performed in triplicate) . Statistical comparisons were estimated using the nonparametric method of Kruskal–
Wallis (one-way ANOVA on ranks), followed by the Dunn's multiple comparisons post hoc test [*p < 0.05; **p 
< 0.01; ***p < 0.001; ****p < 0.0001 vs. control (0 μM)]. 
 
2.2. Flow cytometry analysis of P-glycoprotein expression 
The ability of the tested ATx’s to induce P-gp expression in Caco-2 cells was evaluated by 
flow cytometry, using a P-gp monoclonal antibody [UIC2] conjugated with PE. 
As shown in Figure 19, ATx 2 and ATx 6 significantly increased P-gp expression to 131 and 
130%, respectively, when compared to control cells. For ATX 1 and ATX 5, although a slight 
increase in P-gp expression was observed, no significance was obtained when compared to 
control cells. Furthermore, for ATx 3, ATx 4, ATx 7 and ATx 8, no significant effect on P-gp 
expression was observed after 24 hours of incubation. 
 
 
 
 
 
 
 
 
Figure 19 - Flow cytometry analysis of P-glycoprotein expression levels in Caco-2 cells exposed to ATx’s 1-8 
(20 µM) for 24 hours. Results are presented as mean ± standard error mean (SEM) from 2 independent 
experiments (performed in duplicate). Statistical comparisons were made using One-way ANOVA, followed by 
Tukey's multiple comparisons test [**p < 0.01 vs. control (0 µM)]. 
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2.3. Evaluation of P-glycoprotein transport activity  
The evaluation of P-gp transport activity was determined by flow cytometry using 
rhodamine (RHO) 123, a P-gp fluorescent substrate (20, 40). Two different approaches 
were performed. 
In the first approach, RHO 123 accumulation was evaluated in the presence of the tested 
ATx’s 1-8 (20 μM) during the RHO 123 accumulation phase that lasted 60 minutes, in order 
to evaluate the potential immediate effects of the tested compounds on P-gp activity as a 
result of a direct activation of the pump. P-gp activity was evaluated through the ratio 
between the mean intracellular RHO123 fluorescence intensity (MFI) obtained under P-gp 
inhibition (IA) and the MFI observed in normal conditions (NA, in the absence of P-gp 
inhibition). A higher ratio results from a smaller MFI NA, which is a consequence of a higher 
P-gp activity as the dye is being pumped out of the cells during the accumulation phase. 
As observed in Figure 20, all the tested compounds induced a significant increase in P-gp 
activity, when compared to control cells. From the tested ATx’s, ATx 2 and ATx 7 were the 
most efficient P-gp activators, as revealed by the increased P-gp activity that resulted from 
an increased RHO 123 efflux (P-gp activity significantly increased to 132 and 131 %, 
respectively, when compared to control cells).  
Figure 20 - P-glycoprotein activity evaluated through the RHO 123 accumulation in the presence of ATx’s (20 
µM) during the RHO123 accumulation phase. Results are presented as mean ± SEM from 5 independent 
experiments (performed in triplicate). Statistical comparisons were estimated using One-way ANOVA, followed 
by Tukey's multiple comparisons test [*p < 0.05; ***p < 0.001; ****p < 0.0001 vs. control (0 μM)]. 
In the second approach, RHO 123 accumulation was evaluated in Caco-2 cells pre-exposed 
to the tested ATx’s (20 μM) for 24 hours. With this second protocol, it is possible to evaluate 
whether the increased P-gp expression induced by the ATx’s is accompanied by the 
corresponding increases in P-gp activity, given that an increased protein expression does 
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not necessarily translates into an increased transport activity (Silva et al. 2014a; Takara et 
al. 2009). 
The obtained results (Figure 21) demonstrated a significant increase in P-gp activity for 
seven of the tested compounds, namely ATx 1, ATx 2, ATx 4, ATx 5, ATx 6, ATx 7 and ATx 
8. In fact, P-gp activity increased to 163, 167, 147, 176, 169, 167 and 165 % for ATx 1, ATx 2, 
ATx 4, ATx 5, ATx 6, ATx 7 and ATx 8, respectively. 
For ATx 3, no significant increase in P-gp activity was observed when compared to control 
cells (P-gp activity increased only to 115 %).  
 
  
 
 
 
 
 
 
 
Figure 21 - P-glycoprotein activity evaluated through the RHO 123 accumulation in Caco-2 cells exposed to 
ATx’s (20 µM) for 24 hours. Results are presented as mean ± SEM from 4 independent experiments (performed 
in duplicate). Statistical comparisons were estimated using One-way ANOVA, followed by Tukey's multiple 
comparisons test [***p < 0.001; ****p < 0.0001 vs. control (0 μM)]. 
 
2.4. Determination of ATPase activity 
The effects of ATx's 1-8 on the ATPase activity of P-gp was evaluated through of detection 
and quantification of the unmetabolized ATP, as a luciferase-generated luminescent signal, 
in human P-gp-enriched membranes. P-gp-dependent decreases in luminescence reflect 
ATP consumption by P-gp and, consequently, a decrease in the obtained signal reflects the 
presence of a compound that stimulates P-gp ATPase activity.  
In the present study, Na3VO4 (sodium orthovanadate) was used as a selective P-gp inhibitor 
and, thus, samples treated with Na3VO4 have no P-gp ATPase activity. Consequently, the 
difference in luminescent signal between Na3VO4-treated samples and untreated samples 
(ΔRLUbasal) reflects the basal P-gp ATPase activity, whereas the difference in luminescent 
signal between Na3VO4-treated samples and samples treated with the test compound (TC) 
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(ΔRLUTC) represents the P-gp ATPase activity in the presence of the test compound. 
Therefore, the test compound can be a stimulator of P-gp ATPase activity, if ΔRLUTC > 
ΔRLUbasal; can be an inhibitor of P-gp ATPase activity, if ΔRLUTC < ΔRLUbasal; or can have 
no effect on P-gp ATPase activity , if ΔRLUTC = ΔRLUbasal. Verapamil was used in the present 
assay as a positive control since it is a substrate for P-gp-mediated transport thus 
stimulating P-gp ATPase activity.The results for the eight tested compounds and verapamil 
(Ver) are shown in Figure 22, as well as the basal P-gp ATPase activity. 
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Figure 22 – P-gp ATPase activity in the presence of ATx’s 1-8. Results are expressed as mean ± SEM from 3 
independent experiments (performed in triplicate). Statistical comparisons were estimated using One-way 
ANOVA, followed by Tukey's multiple comparisons test [**p < 0.01 vs. basal P-gp ATPase activity]. 
 
None compound tested (ATx's 1-8) caused a significant change in the Δ RLU in relation to 
the basal P-gp ATPase activity. 
 
2.5. Discussion 
Caco-2 cells express P-gp at levels like those found in normal human jejunum (99) and they 
were already validated as a suitable in vitro model for the evaluation of P-gp modulation 
(20, 25). 
P-gp plays an important role in the pharmacokinetics of a large range of drugs and, 
consequently, the level of expression and functionality of this efflux transporter can greatly 
affect the therapeutic effectiveness of many drugs. Accordingly, is essential to study the 
influence of P-gp expression and activity levels in drug discovery and development. 
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Thioxanthones are a class of interesting compounds due the numerous demonstrated 
biological properties, namely the P-gp modulation ability. Although the studies on their 
ability to modulate P-gp expression and activity are still sparse, some compounds of this 
class were already reported to increase or decrease P-gp expression/activity (40, 46). 
In order to find dual inhibitors of P-gp and tumor cell growth, the P-gp activity in cells 
exposed to different thioxanthonic derivatives was previously analysed. In those studies, for 
fifteen of the investigated compounds it was observed an effect compatible with P-gp 
inhibition, three of them with an effect similar to that elicited by the known P-gp inhibitor, 
quinidine, and higher than the known thioxanthone hycanthone. In opposition, twelve 
derivatives showed a significant decrease in the RHO123 accumulation, an effect compatible 
with P-gp activation. Furthermore, several aminated thioxanthones demonstrated to be 
highly effective at inhibiting P-gp in a chronic myelogenous leukemia cell line, K562 cells, 
suggesting a potential use in reducing multi-drug resistance (40). 
More recently, in a study focused on P-gp induction as an antidotal strategy to prevent PQ-
mediated cytotoxicity, it was evaluated the ability of five thioxanthones to act as P-gp 
inducers and also their ability to immediately increase the pump activity as a consequence 
of a direct activation of the pump (46). In this study, all the tested ATx’s significantly 
increased both P-gp expression and activity in Caco-2 cells, 24 hours after exposure, being  
the first report on the ability of such compounds to act as P-gp inducers. Moreover, although 
it is known that increases in protein expression may not necessarily result in proportional 
increases in the pump activity, for these compounds, the detected increases in the cell 
surface P-gp expression (since the UIC2 monoclonal antibody used in the experiments 
recognizes an external P-gp epitope) were accompanied by similar increases in its transport 
activity. An important aspect to note among the obtained data was the ability of all the tested 
thioxanthonic compounds to rapidly and significantly increase P-gp activity, without 
interfering with its expression, an effect compatible with a P-gp activation phenomenon. 
Contrarily to what was observed in the previously mentioned study, in the present work, the 
data obtained for the eight tested compounds demonstrated that, although not all aminated 
thioxanthones (ATx’s 1-8) caused a significant increase in P-gp expression 24 hours after 
exposure, all the tested compounds significantly increased P-gp activity. In fact, and as 
previously mentioned, it is known that increases in protein expression may not result 
necessarily in proportional increases in pump activity, and that increases in activity can be 
observed independently of the level of expression. 
Furthermore, the tested ATx's 1-8 demonstrated to be P-gp activators since they were able 
to significantly increase P-gp transport function without interfering with the protein 
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expression levels, such as demonstrated by the data obtained in the RHO 123 accumulation 
assay performed in the presence of the ATx’s during a short 60 minutes’ accumulation 
phase. The RHO 123 accumulation evaluated using this protocol does not reflects a possible 
contribution of an increased P-gp expression in the increased activity due to the short 
duration of the contact between the ATx’s and the cells during the RHO 123 accumulation 
phase.  
Curiously, although ATx 1, 4, 5, 7 and 8 were not able to significantly increase P-gp 
expression 24 hours after exposure, a significant increased P-gp activity was observed in 
Caco-2 cells pre-exposed to the tested compounds for this incubation period. Therefore, 
since these compounds demonstrated to be P-gp activators (as demonstrated by the 
significant differences observed in the RHO123 accumulation assay performed with the 
compounds present only the short RHO123 accumulation phase), the observed increases in 
the pump activity may result from a direct pump activation, instead of an increased P-gp 
expression. The observed P-gp activation may be caused by the compound  that remains 
intracellularly, once the cells are pre-exposed to the tested compounds for 24 h, and then 
washed (to remove the tested compounds) prior to the evaluation of P-gp activity by the 
RHO123 accumulation assay. In what concerns to P-gp ATPase activity, no significant 
differences were observed between the P-gp ATPase activity observed in the presence of the 
tested compounds and the basal P-gp ATPase activity. Therefore, as ATx's 1-8 seem to not 
affect the P-gp ATPase activity, there are unlikely to be substrates for P-gp-mediated 
transport, since P-gp substrates, like verapamil, typically stimulate its ATPase activity.  
All compounds tested were synthesized in enantiomeric pure form in order to study the 
effect of the enantioselectivity in P-gp modulation.  
It is known that stereoselectivity of P-gp may be a result of differences in the transport of 
enantiomers, and may, consequently, affect the effectiveness and safety of several drugs (9). 
Although, until the present date, no studies were reported focusing the stereoselectivity of 
thioxanthones in modulating P-gp, some examples of enantioselective modulation of P-gp 
with other scaffolds have already been described (92-94, 97).  
An interesting example of this enantioselectivity is observed with mefloquine, since 
(11R,12S)-(+)-mefloquine presents a much higher human brain penetration than (11S,12R)-
(-)-mefloquine (94). Furthermore, P-gp can be modulated in a different way by enantiomers 
as described for cetirizine, which up-regulated P-gp expression with the (R)-enantiomer 
and down-regulates by it with treatment with (S)-cetirizine (82, 93).  
Comparing the results obtained for the studied enantiomeric pairs (ATx 1 and ATx 2, ATx 
3 and ATx 4, ATx 5 and ATx 6, and ATx 7 and ATx 8), no significant differences in P-gp 
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expression neither in P-gp activity were observed. Consequently, this library of compounds 
did not put in evidence the stereoselective modulation of P-gp as previously observed for 
other substrates, such as for mefloquine enantiomers. Future in silico studies will be 
performed and may help to explain the obtained experimental results. 
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Conclusions 
Thioxanthonic derivatives and, particularly, aminated thioxanthones, have been 
characterized as P-gp modulators. Since the pharmacokinetics, efficacy and safety of drugs 
that are P-gp substrates depend on the level of expression and functionality of P-gp, and can 
be affected by the chirality, it is important to better understand the effect that 
enantioselectivity may have in P-gp modulation.  
Therefore, in order to accomplish the main aim of this study, four enantiomeric pairs of 
thioxanthonic derivatives were synthesized, in an enantiomerically pure form. The reaction 
conditions used in the Ullmann cross coupling reaction between a suitable functionalize 
thioxanthone with chiral building blocks allowed a successful synthesis of the desirable 
thioxanthones.  
Spectroscopic methods (IR, 1H NMR, 13C NMR, and bidimensional HSQC and HMBC) 
allowed the unambiguous elucidation of all the thioxanthonic derivatives (ATx 1-8) and the 
absolute values of specific rotation confirmed that no racemization occurred under these 
reaction conditions. Moreover, the purification process applied allowed to obtain the 
desirable thioxanthones with a purity of at least 95 % and with enough amounts to proceed 
with the evaluation of their biological activity. 
The assay carried out for evaluation of the biological activity of the tested ATx's 1-8 have 
the ability the increase the P-gp activity without interfering with its levels of expression and, 
therefore, can be characterized as P-gp activators. ATx 2 and ATx 7 demonstrated to be the 
more efficient P-gp activators, among all the aminated thioxanthones tested. 
Comparing the results obtained with enantiomers (R) and (S), no significant 
enantioselectivity was observed for all the tested enantiomeric pairs.  
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PART I – CHEMISTRY 
 
1.1. General methods 
All reagents and solvents were purchased from Sigma Aldrich, and had no further 
purification process. Solvents were evaporated using rotary evaporator under reduced 
pressure, Buchi Waterchath B-480.  
Reactions were performed in a muffle for 48 hours at 1000 C. All reactions were monitored 
by TLC carried out on precoated plates with 0.2 mm of thickness using Merck silica gel 60 
(GF254). The UV light at 254 and 365 nm or/and chemical.   
Flash column chromatography using Merck silica gel 60 (0.040-0.063 mm), flash cartridge 
chromatography (GraceResolv®, Grace Company, Deerfield, IL, USA), and Discovery® 
DSC-SCX SPE cationic exchange cartridge were used in the purification of the synthesized 
compounds.  
Melting points (m.p.) were obtained in a Köfler microscope and are uncorrected. Infrared 
(IR) spectra were obtained in KBr microplates in a Fourier transform infrared spectroscopy 
spectrometer Nicolet iS10 from Thermo Scientific with Smart OMNI-Transmisson 
accessory (Software OMNIC 8.3) (cm-1).  
Optical rotation measurements were carried out on a Polartronic Universal polarimeter 
using dichloromethane as solvent.  
NMR spectra were performed in University of Aveiro, Department of Chemistry, and were 
taken in CDCl3 (Deutero GmbH) at room temperature on Bruker Avance 300 spectrometer 
(300.13 MHz for 1H and 75.47 MHz for 13C). 13C NMR assignments were made by 
bidimentional HSQC and HMBC experiments (long-range C, H coupling constants were 
optimized to 7 and 1 Hz) or by comparison with the assignments of similar molecules. 
HPLC analyses were performed by Dr. Sara Cravo, Department of Chemistry, Laboratory of 
Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto. The 
HPLC analysis was performed on a Finnigan Surveyor equiped with diode array detector 
TSP UV8000LP.  Chromatographic separation was carried out on 250 × 4.6 mm i.d. 
FortisBIO C18 column (5 μM) with the mobile phase MeOH:H2O:TEA (80:20:0.5 v/v/v). 
The flow rate was 1 ml/min.  An aliquot of 20 μL of each synthesized tioxanthone derivative 
(ATx’s 1-8) was injected into the HPLC system. 
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1.2. Synthesis of thioxanthonic derivatives 
1.2.1 General procedure 
The 1-chloro-4-propoxy-9H-thioxanthen-9-one (Tx, 450 mg, 1.48 mmol) and suitable chiral 
amino alcohol precursor (A 10-17, 1.72 mmol) were dissolved in methanol (30 mL) and CuI 
(0.15 mmol) and K2CO3 (1.92 mmol) were added. The reaction mixture was heated at 1000 
C in a muffle for 48 hours, and monitored by TLC using the mobile phase 
chloroform/acetone 9.7:0.3 (v/v). After the completion of the reaction, the crude material 
was filtrated, washed with dichloromethane and was dried and concentrated under reduced 
pressure. Then, the solid was dissolved in 50 mL of dichloromethane and extracted with 
HCl 1M (3 × 50mL). The aqueous layer was basified with NaOH 20% and extracted with 
dichloromethane (3 × 100 mL). The organic layers were gathered, washed with water (50 
mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure. 
Then, a solid phase extraction with a cation exchange cartridge Discovery ® DSC-SCX was 
applied to the extract material, as following: activation of the cartridge with 
dichloromethane (50 mL); loading the cartridge with the sample (previously incorporated 
in silica); elution with dichloromethane; elution with a mixture of 
dichloromethane/methanol 5:5 (v/v); elution with methanol 100%; elution with NH3 2% 
in methanol. All the fractions were controlled by TLC using as mobile phase chloroform/ 
acetone 9.7: 1.3. The fractions containing the thioxanthonic derivatives were gathered and 
concentrated under reduced pressure. The solids obtained was subjected to different work-
up strategies as described below. 
1.2.2. Synthesis of (S)-1-((1-hydroxypropan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 1) (1) 
 The solid obtained following the general procedure (section 1.2.1.) was then purified by a 
flash column chromatography with n-hexane/ ethyl acetate in gradient and crystallized 
from chloroform and petroleum ether (4:1). The procedure allowed obtaining the desirable 
compound ATx 1 (1) as a red solid in 1.97 % yield (10.0 mg). 
ATx 1 (1): m.p: 116 - 118 ℃; [𝜶]𝑫
𝟐𝟓℃ +112° (c = 3.4 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3419, 3270, 2962, 2925, 2873, 2359, 2341, 1618, 1568, 1507, 1435, 1293, 
1269, 1252, 1225, 746 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.50 (1H, d, J = 8.0 Hz, H-8), : 7.56 (2H, m, H-5 and H-
6), : 7.43 (1H, m, H-7), : 7.13 (1H, d, J = 9.0 Hz, H-3), : 6.85 (1H, d, J = 9.0 Hz, H-2), : 
4.03 (2H, t, J = 6.5 Hz, H-a), : 3.81 (3H, m, H-1’ and CH2OH), : 1.90 (2H, m, H-b), : 1.32 
(3H, d, J = 6.2 Hz, H-2’), : 1.12 (3H, t, J = 7.4 Hz, H-c). 
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13C NMR (75.47 MHz, CDCl3): : 183.55 (C-9), 146.50 (C-4), 144.02 (C-1), 136.85 (C-6), 
131.92 (C-8a), 129.85 (C-4a), 129.24 (C-9a), 126.08 (C-8), 125.98 (C-7), 125.20 (C-5), 119.12 
(C-3), 114.10 (C-10a), 109.80 (C-2), 72.48 (C-a), 65.96 (C-CH2OH), 51.91 (C-1’), 22.66 (C-
b), 16.86 (C-2’), 10.71 (C-c). 
 
1.2.3. Synthesis of (R)-1-((1-hydroxypropan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 2) (2) 
The solid obtained with the general procedure (section 1.2.1.) was subject to the same 
purification procedures as described above for the ATx 1 (1), allowing to obtain the desirable 
compound 2 as a red solid in 5.91 % yield (30.0 mg). 
 ATx 2 (2): m.p: 118 - 120 ℃; [𝜶]𝑫
𝟐𝟓℃ - 112° (c = 3.4 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3447, 3282, 2963, 2927, 2874, 1611, 1595, 1569, 1506, 1436, 1290, 1270, 
1252, 1226, 1072, 795, 746 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.50 (1H, d, J = 8.1 Hz, H-8), : 7.56 (2H, m, H-5 and H-
6), : 7.42 (1H, m, H-7), : 7.13 (1H, d, J = 9.1 Hz, H-3), : 6.82 (1H, d, J = 9.1 Hz, H-2), : 
4.04 (2H, t, J = 6.5 Hz, H-a), : 3.78 (3H, m, H-1’ and CH2OH), : 1.90 (2H, m, H-b), : 1.33 
(3H, d, J = 6.3 Hz, H-2’), : 1.11 (3H, m, H-c). 
13C NMR (75.47 MHz, CDCl3): : 183.56 (C-9), 146.80 (C-4), 144.00 (C-1), 136.82 (C-6), 
131.87 (C-8a), 129.91 (C-4a), 129.22 (C-9a), 126.05 (C-8), 125.97 (C-7), 125.20 (C-5), 119.35 
(C-3), 114.00 (C-10a), 109.02 (C-2), 72.52 (C-a), 66.04 (C-CH2OH), 51.55 (C-1’), 22.70 (C-
b), 17.00 (C-2’), 10.71 (C-c). 
 
1.2.4. (S)-1-((2-hydroxypropyl)amino)-4-propoxy-9H-thioxanthen-9-one (ATx 
3) (3) 
The solid obtained with the general procedure (section 1.2.1.) was then crystallized from 
chloroform and petroleum ether, to obtain the desirable compound 3 as a red solid in 7.86 
% yield (40.0 mg). 
 ATx 3 (3): m.p: 149-152 ℃; [𝜶]𝑫
𝟐𝟓℃ - 12° (c = 6.67 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3460, 3320, 2965, 2933, 2875, 1607, 1566, 1556, 1502, 1450, 1434, 1286, 
1269, 1249, 1227, 1158, 1133, 1060, 744 cm-1.    
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1H NMR (300.13 MHz, CDCl3): : 8.52 (1H, d, J = 8.1 Hz, H-8), : 7.56 (2H, m, H-5 and H-
6), : 7.42 (1H, m, H-7), : 7.13 (1H, d, J = 9.0 Hz, H-3), : 6.78 (1H, d, J = 9.0 Hz, H-2), : 
4.26 (1H, m, H-2’), : 4.03 (2H, t, J = 6.5 Hz, H-a), : 3.30 (2H, m, H-1’), : 1.90 (2H, m, H-
b), : 1.35 (3H, d, J = 6.3, CH3), : 1.12 (3H, t, J = 7.4, H-c). 
13C NMR (75.47 MHz, CDCl3): : 183.46 (C-9), 146.18 (C-4), 144.01 (C-1), 136.98 (C-6), 
133.27 (C-8a), 129.54 (C-4a), 129.43 (C-9a), 127.19 (C-8), 126.32 (C-7), 126.10 (C-5), 117.94 
(C-3), 115.36 (C-10a), 111.83 (C-2), 72.31 (C-a), 65.58 (C-2’), 54.12 (C-1’), 22.74 (C-b), 20.97 
(C-CH3), 14.15 (C-c). 
 
1.2.5. (R)-1-((2-hydroxypropyl)amino)-4-propoxy-9H-thioxanthen-9-one (ATx 
4) (4) 
The general procedure (section 1.2.1.) allowed to obtain the desirable compound 4 as a red 
solid in 23.62 % yield (120.0 mg). 
 ATx 4 (4): m.p: 145-150 ℃; [𝜶]𝑫
𝟐𝟓℃ + 12° (c = 6.67 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3460, 3323, 2966, 2932, 2875, 1606, 1566, 1556, 1501, 1451, 1434, 1328, 
1286, 1270, 1249, 1227, 1158, 1133, 1102, 1060, 972, 744 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.51 (1H, d, J = 8.0 Hz, H-8), : 7.50 (2H, m, H-5 and H-
6), : 7.41 (1H, m, H-7), : 7.12 (1H, d, J = 9.0 Hz, H-3), : 6.73 (1H, d, J = 9.0 Hz, H-2), : 
4.22 (1H, m, H-2’), : 4.03 (2H, t, J = 6.4 Hz, H-a), : 3.29 (2H, m, H-1’), : 1.90 (2H, m, H-
b), : 1.35 (3H, d, J = 6.3, CH3), : 1.12 (3H, t, J = 7.4, H-c). 
13C NMR (75.47 MHz, CDCl3): : 183.46 (C-9), 147.48 (C-4), 143.91 (C-1), 136.81 (C-6), 
131.83 (C-8a), 129.92 (C-4a), 129.85 (C-9a), 129.26 (C-8), 126.02 (C-7), 125.95 (C-5), 119.25 
(C-3), 113.95 (C-10a), 108.42 (C-2), 72.47 (C-a), 66.11 (C-2’), 52.07 (C-1’), 22.85 (C-b), 21.02 
(C-CH3), 10.71 (C-c). 
 
1.2.6. (S)-1-((1-hydroxy-4-methylpentan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 5) (5) 
The general procedure (section 1.2.1.) allowed obtaining the desirable compound 5 as a red 
solid in 19.59 % yield (111.8 mg). 
 ATx 5 (5): m.p: 82-85 ℃; [𝜶]𝑫
𝟐𝟓℃ - 68° (c = 6.75 x 10−3g/mL in dichloromethane). 
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IR (KBr) v max:  3457, 3290, 2955, 2923, 2870, 1613, 1595, 1566, 1505, 1464, 1435, 1386, 
1265, 1224, 1107, 1067, 1018, 745 cm-1.  
1H NMR (300.13 MHz, CDCl3): : 8.51 (1H, d, J = 8.1 Hz, H-8), : 7.57 (2H, m, H-5 and H-
6), : 7.42 (1H, m, H-7), : 7.13 (1H, d, J = 9.0 Hz, H-3), : 6.93 (1H, d, J = 9.0 Hz, H-2), : 
4.04 (2H, t, J = 6.5 Hz, H-a), : 3.88 (1H, dd, J = 10.1 Hz, H-1’), : 3.71 (2H, m, CH2OH), : 
1.85 (4H, m, H-b), :1.78 (1H, m, H-3’), : 1.57 (1H, t, J = 6.9 Hz, H-2’), : 1.12 (3H, t, J = 
7.4 Hz, H-c), : 0.94 (3H, d, J = 6.5 Hz, H-4’a), : 0.89 (3H, d, J = 6.5 Hz, H-4’b). 
13C NMR (75.47 MHz, CDCl3): : 183.61 (C-9), 145.00 (C-4), 142.80 (C-1), 136.7 (C-6), 131.98 
(C-8a), 129.97 (C-4a), 129.83 (C-9a), 129.28 (C-8), 126.11 (C-7), 126.00 (C-5), 119.05 (C-3), 
114.43 (C-10a), 111.02 (C-2), 72.45 (C-a), 64.62 (C-1’), 55.01 (C-CH2OH), 40.44 (C-2’), 24.90 
(C-3’), 22.86 (C-4’a), 22.83 (C-4’b), 22.61 (C-b), 10.71 (C-c). 
 
1.2.7. (R)-1-((1-hydroxy-4-methylpentan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 6) (6) 
The general procedure (section 1.2.1.) allowed to obtain the desirable compound 6 as a red 
solid in 10.40 % yield (59.3 mg). 
 ATx 6 (6): m.p: 80-82 ℃; [𝜶]𝑫
𝟐𝟓℃ +56 ° (c = 6.75 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3459, 3291, 2954, 2925, 2871, 1613, 1595, 1566, 1505, 1480, 1435, 1386, 1266, 
1224, 1108, 1072, 1018, 746 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.51 (1H, d, J = 8.1 Hz, H-8), : 7.55 (2H, m, H-5 and H-
6), : 7.42 (1H, m, H-7), : 7.12 (1H, d, J = 9.1 Hz, H-3), : 6.86 (1H, d, J = 9.1 Hz, H-2), : 
4.03 (2H, t, J = 6.5 Hz, H-a), : 3.85 (1H, dd, J = 10.5 , H-1’), : 3.72 (2H, m, CH2OH), : 
1.83 (4H, m, H-b), : 1.76 (1H, m, H-3’), : 1.57 (1H, t, J = 6.9 Hz, H-3’), : 1.12 (3H, t, J = 
7.4 Hz, H-c), : 0.96 (3H, d, J = 6.5 Hz, H-4’a), : 0.89 (3H, d, J = 6.5 Hz, H-4’b). 
13C NMR (75.47 MHz, CDCl3): : 183.61 (C-9), 145.00 (C-4), 142.80 (C-1), 136.82 (C-6), 
131.87 (C-8a), 129.93 (C-4a), 129.24 (C-9a), 128.80 (C-8), 126.03 (C-7), 125.97 (C-5), 119.42 
(C-3), 113.94 (C-10a), 108.80 (C-2), 72.49 (C-a), 64.87 (C-1’), 40.71 (C-2’), 24.92 (C-3’), 
22.96 (C-4’a), 22.86 (C-4’b), 22.55 (C-b), 10.71 (C-c). 
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1.2.8. (S)-1-((1-hydroxy-3-methylbutan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 7) (7) 
The general procedure allowed (section 1.2.1.)  to obtain the desirable compound 7 as a red 
solid in 10.12 % yield (55.6 mg). 
ATx 7 (7): m.p: 98-102 ℃; [𝜶]𝑫
𝟐𝟓℃ - 26° (c = 6.80 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3385, 3256, 2960, 2926, 2873, 2360, 1614, 1569, 1514, 1463, 1434, 1386, 
1329, 1267, 1249, 1225, 1165, 1070, 1021, 744 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.54 (1H, d, J = 8.0 Hz, H-8), : 7.59 (2H, m, H-5 and H-
6), : 7.45 (1H, m, H-7), : 7.14 (1H, d, J = 9.1 Hz, H-3), : 7.07 (1H, d, J = 9.1 Hz, H-2), : 
4.06 (2H, t, J = 6.4 Hz, H-a), : 3.86 (2H, m, CH2OH),: 3.53 (1H, m, H-1’),  : 2.08 (1H, 
m,  H-2’) : 1.91 (2H, m, H-b), : 1.05 (3H, d, J = 6.9 Hz, H-3’a), : 0.87 (3H, d, J = 6.9 Hz, 
H-3’b), : 1.12 (3H, t, m, H-c). 
13C NMR (75.47 MHz, CDCl3): : 183.43 (C-9), 145.0 (C-4), 142.8 (C-1), 136.43 (C-6), 131.66 
(C-8a), 129.53 (C-4a), 129.03 (C-9a), 128.84 (C-8), 125.70 (C-7), 125.51 (C-5), 117.82 (C-3), 
114.71 (C-10a), 111.6 (C-2), 71.80 (C-a), 63.93 (C-1’), 61.56 (C-CH2OH), 29.15 (C-2’), 22.21 
(C-b), 18.53 (C-3’a), 18.41 (C-3’b), 10.14 (C-c). 
 
1.2.9. (R)-1-((1-hydroxy-3-methylbutan-2-yl)amino)-4-propoxy-9H-
thioxanthen-9-one (ATx 8) (8) 
After the general procedure (section 1.2.1.), the solid obtained was crystallized using an 
identical procedure of section 1.2.4, allowing to obtain the desirable compound 8 as a red 
solid in 10.24 % yield (75.0 mg). 
 ATx 8 (8): m.p: 98-104 ℃; [𝜶]𝑫
𝟐𝟓℃ + 26° (c = 6.80 x 10−3g/mL in dichloromethane). 
IR (KBr) v max:  3423, 3272, 2959, 2925, 2872, 1611, 1570, 1511, 1463, 1435, 1385, 1251, 1226, 
1161, 1068, 1022, 747 cm-1. 
1H NMR (300.13 MHz, CDCl3): : 8.56 (1H, d, J = 8.0 Hz, H-8), : 7.64 (2H, m, H-5 and H-
6), : 7.49 (1H, m, H-7), : 7.34 (1H, d, J = 8.9 Hz, H-3), : 7.17 (1H, d, J = 8.9 Hz, H-2), : 
4.10 (2H, t, J = 6.4 Hz, H-a), : 3.90 (2H, m, CH2OH),: 3.50 (1H, m, H-1’),  : 2.10 (1H, m,  
H-2’) : 1.91 (2H, m, H-b), : 1.02 (3H, d, J = 6.9 Hz, H-3’a), : 0.98 (3H, d, J = 6.9 Hz, H-
3’b), : 1.14 (3H, t, m, H-c);  
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13C NMR (75.47 MHz, CDCl3): : 183.65 (C-9), 147.74 (C-4), 141.53 (C-1), 137.16 (C-6), 
132.60 (C-8a), 130.43 (C-4a), 129.52 (C-9a), 129.21 (C-8), 126.52 (C-7), 126.19 (C-5), 117.12 
(C-3), 116.69 (C-10a), 115.38 (C-2), 72.19 (C-a), 67.02 (C-1’), 61.17 (CH2OH), 28.87 (C-2’), 
22.65 (C-b), 19.31 (C-3’a), 18.58 (C-3’b), 10.69 (C-c). 
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PART II - BIOLOGICAL ACTIVITY 
 
2.1.  Material 
Dulbecco’s modified Eagle’s medium (high glucose), RHO 123, elacridar and neutral red 
(NR) solution were obtained from Sigma (St. Louis, MO, USA). 
Reagents used in cell culture, including nonessential amino acids (NEAA), heat inactivated 
fetal bovine serum (FBS), 0.25% trypsin/1 mM EDTA, antibiotic (10,000 U/mL penicillin, 
10,000 μg/mL streptomycin) and human transferrin (4 mg/mL) were purchased from 
Gibco Laboratories (Lenexa, KS, USA). P-glycoprotein monoclonal antibody (clone UIC2) 
conjugated with with phycoerythrin (PE) was purchased from Abcam (Cambridge, United 
Kingdom). Flow cytometry reagents (sheath fluid, cleaning solution, decontamination 
solution, extended flow cell clean) were purchased from BD Bioscience Pgp-Glo™ Assay 
System was purchased from Promega Corporation (Madison, USA). All the reagents used 
were of analytical grade or of the highest grade available.  
 
2.2 Caco-2 cell culture 
Caco-2 cells, derived from human colorectal adenocarcinoma, were routinely cultured in 75 
cm2 flasks using Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
heat-inactivated fetal bovine serum (FBS), 100 μM nonessential amino acids (NEAA), 100 
U/mL penicillin, 100 µg/mL streptomycin and 6 μg/mL transferrin. 
Cells were maintained in a 5 % CO2-95 % air atmosphere, at 37 °C, and the medium was 
changed every 2 to 3 days. Cultures were passaged weekly by trypsinization (0.25 % 
trypsin/1 mM EDTA). The cells used for all the experiments were taken between the 27th 
and 36th passages. 
For the cytotoxicity assays, the cells were seeded in 96-well plates at a density of 60,000 
cells/cm2 and used 3 days after seeding, when confluence was reached. 
For the experiments performed for the evaluation of P-glycoprotein expression and P-
glycoprotein transport activity, the cells were seeded in 12-well plates at a density of 60,000 
cells/cm2 and used 3 days after seeding. 
 
2.3. Cytotoxicity assays 
The NR uptake assay is based on the ability of viable cells to incorporate and bind the 
supravital dye NR in the lysosomes, thus providing a quantitative estimation of the number 
of viable cells in a culture (46).  
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Aminated thioxanthones 1-8 (0–50 μM) cytotoxicity was evaluated, 24 hours after 
exposure, by the NR uptake assay. Briefly, the cells were seeded onto 96-well plates at a 
density of 60,000 cells/cm2, and exposed, after reaching confluence, to the eight tested 
ATx’s (0–50 μM) in fresh cell culture medium. Twenty-four hours after exposure, the cells 
were incubated with NR (40 μg/mL in cell culture medium) at 37 °C, in a humidified, 5 % 
CO2-95 % air atmosphere, for 60 minutes. After this incubation period, the cell culture 
medium was removed, the dye absorbed only by viable cells extracted [with absolute ethyl 
alcohol/distilled water (1:1) containing 5 % acetic acid] and the absorbance measured at 540 
nm in a multiwall plate reader (BioTek Synergy™ HT, BioTek Instruments). The percentage 
of NR uptake relative to that of the control cells was used as the cytotoxicity measure. 
 
2.4. Flow cytometry analysis of P-glycoprotein expression 
For the in vitro evaluation of P-gp expression, the cells were seeded onto 12-well plates, at 
a density of 60,000 cells/ cm2 and exposed, three days after seeding, to the eight tested 
ATx’s 1-8 (20 μM) in fresh cell culture medium for 24 hours. 
After the incubation period, the cells were washed with HBSS buffer and harvested by 
trypsinization (0.25 % trypsin/1 mM EDTA) to obtain a cellular suspension. The cells were 
then centrifuged (300g, for 10 min, at 4 °C) and suspended in HBSS buffer containing the 
P-gp antibody [UIC2] conjugated with PE. The antibody dilution used in this experiment 
was applied according to the manufacturer’s instructions for flow cytometry. The cells were 
then incubated, for 30 min, at 37 °C in the dark. 
After this incubation period, the cells were washed twice with HBSS containing 10 % heat-
inactivated FBS, centrifuged (300g for 10 min), suspended in ice-cold HBSS buffer and kept 
on ice until analysis. Fluorescence measurements of isolated cells were performed with a 
flow cytometer (BD AccuriTM C6). 
The fluorescence of the PE-UIC2 antibody was measure by a 585 ± 40 nm band-pass filter 
(FL2). The logarithmic fluorescence was recorded and displayed as a single parameter 
histogram, and based on the acquisition of data for 20,000 cells. 
The mean of fluorescence intensity (MFI) was the parameter used for comparison 
[calculated as percentage of control (0 μM)]. Nonlabeled cells (with or without ATx’s) were 
also analyzed in each experiment by a 585 ± 40 nm band-pass filter (FL2) in order to detect 
a possible contribution from cells autofluorescence to the analyzed fluorescence signals. 
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2.5. Evaluation of P-glycoprotein transport activity 
The P-gp transport activity was evaluated by flow cytometry using RHO 123 (2 μM) as a P-
gp fluorescent substrate. P-gp transport activity was evaluated through the analysis of RHO 
123 accumulation using two different experimental designs: 
 RHO 123 accumulation assay in the presence (IA) and absence (NA) of a P-gp 
inhibitor, elacridar (10 μM), and with or without exposure to the tested 
thioxanthonic compounds (20 μM) only during the RHO 123 accumulation phase; 
 RHO 123 accumulation assay, in the presence (IA) and absence (NA) of a P-gp 
inhibitor, elacridar (10 μM), and with or without pre-exposure to the tested 
thioxanthones (20 μM) for 24h. 
 
 
2.5.1. RHO 123 accumulation assay in the presence of thioxanthones 
Caco-2 cells were seeded onto 75 cm2 flasks and, after reaching confluence, washed with 
HBSS and harvested by trypsinization (0.25 % trypsin/1 mM EDTA) to obtain a cellular 
suspension. This cell suspension was then divided into several aliquots of 300,000 cells, 
which were submitted to the following procedures: 
i. Normal rhodamine accumulation (NA): the cells were centrifuged (300 g for 10 
minutes), suspended in HBSS containing 10% heat-inactivated FBS and 2 μM 
RHO123, with and without 20 M thioxanthones, and incubated at 37º C for 60 min 
in the absence of the P-gp inhibitor (elacridar). After the incubation period the cells 
were washed twice with ice-cold HBSS with 10% heat-inactivated FBS, centrifuged 
(300 g for 10 min) at 4° C and kept on ice until flow cytometry analysis;  
ii. Inhibited rhodamine accumulation (IA): the cells were centrifuged (300 g for 10 
min), suspended in HBSS containing 10% heat-inactivated FBS, 2 μM RHO 123 and 
the P-gp inhibitor elacridar (10 μM), with and without 20 μM thioxanthones, and 
incubated at 37ºC for 60 min. After the accumulation of the fluorescent substrate, 
the cells were washed twice with ice-cold HBBS with 10% heat-inactivated FBS, 
centrifuged (300 g for 10 min) at 4°C and kept on ice until flow cytometry analysis. 
Fluorescence measurements of isolated cells were performed as described in section 
“Evaluation of P-gp expression”. The green intracellular fluorescence of RHO 123 was 
measured by a 530 ± 15 nm band-pass filter (FL1). The results were calculated according to 
the ratio defined in Equation 1 and expressed as percentage of control (0 μM).  
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𝑹𝑯𝑶 𝟏𝟐𝟑 𝑨𝒄𝒄𝒖𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 =  
MFI inhibited rhodamine accumulation (IA)
MFI normal rhodamine accumulation (NA)
 
 
Equation 1. P-gp activity evaluated through rhodamine 123 accumulation ratio. 
 
When P-gp activity increases, the amount of RHO 123 effluxed from the cells is higher and 
accompanied by a decrease in the intracellular fluorescence intensity due to the 
corresponding decrease in the intracellular RHO 123 content. Thus, a higher ratio results 
from a smaller MFI NA, which is a consequence of a higher P-gp activity as the dye is being 
pumped out of the cells during the accumulation phase. 
 
2.5.2. RHO 123 accumulation assay in Caco‑2 cells pre-expose to thioxanthones 
for 24 hours 
Caco-2 cells were seeded onto 12-well plates, at a density of 60,000 cells/cm2, to obtain 
confluent monolayers at the day of the experiment. Three days after seeding, the cells were 
exposed to ATx’s (20 μM), in fresh cell culture medium, for 24 h. After this incubation 
period, the cells were washed with HBSS and harvested by trypsinization (0.25 % trypsin/1 
mM EDTA) to obtain a cell suspension. The cells of each well were divided into two aliquots. 
The first aliquot was submitted to a RHO 123 accumulation phase performed under 
inhibited conditions (RHO 123 accumulation performed in the presence of the P-gp 
inhibitor, elacridar — IA). The second aliquot was submitted to a RHO 123 accumulation 
phase performed under normal conditions (RHO 123 accumulation performed in the 
absence of P-gp inhibitor—NA). For IA accumulation, the cells were centrifuged (300 g for 
10 minutes), suspended in HBSS buffer (pH 7.4) containing 10% heat-inactivated FBS, 2 
µM RHO 123 and the P-gp inhibitor elacridar (10.0 µM), and incubated at 37 ºC for 60 min 
to allow RHO 123 accumulation. For NA accumulation, a similar incubation was performed 
but in the absence of the P-gp inhibitor. After this accumulation period, the cells were 
washed twice with ice-cold HBSS buffer containing 10 % heat-inactivated FBS and 
suspended in ice-cold wash solution immediately before analysis. The fluorescence 
measurements of isolated cells were performed as described in “Flow cytometry analysis of 
P-glycoprotein expression” section. The green intracellular fluorescence of RHO 123 was 
measured by a 530 ± 15 nm band-pass filter (FL1). The results were calculated according to 
the ratio defined in Equation 1 and expressed as percentage of control values. 
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2.6. Determination of ATPase activity 
The effects of the tested thioxanthones on P-gp ATPase activity were evaluated using the 
luminescen Pgp-Glo™ Assay (Promega), according to the manufacturer's protocol, using 
recombinant human P-gp-enriched membranes. 
Briefly, recombinant human P-gp-enriched membranes (25 μg/ well) were incubated with   
 20 μM ATx’s or sodium vanadate at 100 μM (positive control for P-gp ATPase activity 
inhibition) or verapamil at 200 μM (positive control for P-gp ATPase activity stimulation) 
in assay buffer, and 5 mM MgATP for exactly 60 min at 37 °C. After the incubation, the 
reaction was stopped and the remaining ATP detected after a 20 min signal-developing 
period at room temperature, as a luciferase-generated luminescent signal in a multi-well 
plate reader (BioTek Synergy™ HT). 
The decreased luminescence of the untreated (NT) incubations relative to Na3VO4-treated 
incubations reflects basal Pgp ATPase activity. The decreased luminescence of incubations 
performed with the positive control drug verapamil relative to Na3VO4-treated reactions 
reflects verapamil-stimulated Pgp ATPase activity. The luminescence of the ATx’s 
performed incubations relative to that of the Na3VO4-treated reactions reflects the effect, 
if any, of that compounds on P-gp ATPase activity (i.e. a decrease in luminescence reflects 
a stimulated Pgp ATPase activity). Therefore, for data analysis, the following equations were 
thus used to calculate the change in luminescence (ΔRLU) signals: 
 
1. ΔRLUbasal = RLUNa3VO4 – RLUNT, reflecting basal P-gp ATPase activity 
 
2. ΔRLUTC = RLUNa3VO4 – RLUTC, reflecting P-gp ATPase activity in the presence of 
a test compound (TC). 
 
Three independent experiments were performed in triplicate for this assay and the results 
expressed as Mean ± SEM. 
 
2.7. Statistical analysis 
All statistical calculations were performed with the GraphPad Prism version 6.00 for 
Windows (GraphPad Software, San Diego California, USA). Normality of the data 
distribution was assessed by three different tests (KS normality test, D'Agostino & Pearson 
omnibus normality test and Shapiro-Wilk normality test).  
Data obtained from the thioxanthones cytotoxicity assays are expressed as mean ± SEM 
from at least 5 independent experiments (performed in triplicate) and the statistical 
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comparisons were estimated using the nonparametric method of Kruskal–Wallis, followed 
by the Dunn’s post hoc test. Data from the P-gp expression assays are presented as mean ± 
SEM from 2 independent experiments (performed in duplicate) and the statistical 
comparisons were made using One-way ANOVA, followed by theTukey's multiple 
comparisons test. Results from the P-gp transport activity assays performed in the presence 
of ATx’s during the RHO123 accumulation phase are presented as mean ± SEM from 5 
independent experiments (performed in triplicate) and the statistical comparisons were 
estimated using One-way ANOVA, followed by the Tukey's multiple comparisons test. 
Results from the P-gp transport activity assays performed in cells pre-exposed to ATx’s for 
24 h are presented as mean ± SEM from 4 independent experiments (performed in 
duplicate) and the statistical comparisons were estimated using One-way ANOVA, followed 
by the Tukey's multiple comparisons test. Results from the P-gp ATPase activity are 
presented as mean ± SEM from 3 independent experiments (performed in triplicate) and 
the statistical comparisons were estimated using One-way ANOVA, followed by the Tukey's 
multiple comparisons test. In all cases, p values lower than 0.05 were considered significant. 
In all cases, p values lower than 0.05 were considered significant. 
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Table 14 - The chemical structures of the synthesized chiral thioxanthones. 
Synthesized chiral thioxanthones Chemical structures 
ATx 1 (1) 
(S)-1-((1-hydroxypropan-2-yl)amino)-4-
propoxy-9H-thioxanthen-9-one 
 
ATx 2 (2) 
(R)-1-((1-hydroxypropan-2-yl)amino)-4-
propoxy-9H-thioxanthen-9-one 
 
 
ATx 3 (3) 
(S)-1-((2-hydroxypropyl)amino)-4-
propoxy-9H-thioxanthen-9-one 
 
ATx 4 (4) 
(R)-1-((2-hydroxypropyl)amino)-4-
propoxy-9H-thioxanthen-9-one 
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ATx 5 (5) 
(S)-1-((1-hydroxy-4-methylpentan-2-
yl)amino)-4-propoxy-9H-thioxanthen-9-
one 
 
 
ATx 6 (6) 
 
(R)-1-((1-hydroxy-4-methylpentan-2-
yl)amino)-4-propoxy-9H-thioxanthen-9-
one 
 
ATx 7 (7) 
(S)-1-((1-hydroxy-3-methylbutan-2-
yl)amino)-4-propoxy-9H-thioxanthen-9-
one 
 
 
ATx 8 (8) 
 (R)-1-((1-hydroxy-3-methylbutan-2-
yl)amino)-4-propoxy-9H-thioxanthen-9-
one 
 
 
 
